Yayınlar & Eserler

ATLAS Yayın Analitiği
Makaleler 277
Tümü (277)
SCI-E, SSCI, AHCI (248)
SCI-E, SSCI, AHCI, ESCI (268)
ESCI (18)
Scopus (267)
TRDizin (47)
Diğer Yayınlar (2)

1. Comparison of Factors Associated With 30-Day and 90-Day Readmission Among a Global Cohort of Patients Hospitalised With Cirrhosis

İDİLMAN R., Haktaniyan B., Choudhury A., Wong F., Kamath P. S., Xie Q., et al.
Liver International , cilt.46, sa.9, 2026 (SCI-Expanded, Scopus)

2. A global consensus on the critical care management of acute-on-chronic liver failure patients: the APASL ACLF Beijing Position Paper

Chen T., Choudhury A., Liu W., Zhang M., Wu W., Xiang H., et al.
Hepatology International , cilt.20, sa.4, ss.963-991, 2026 (SCI-Expanded, Scopus) Creative Commons License

3. Lack of association between rifaximin and drug-resistant infections: a global multicenter inpatient cirrhosis cohort

Bajaj J. S., Kamath P. S., Wong F., Xie Q., İDİLMAN R., Topazian M., et al.
Clinical and Molecular Hepatology , cilt.32, sa.3, ss.1321-1332, 2026 (SCI-Expanded, Scopus) Creative Commons License

4. TASL practice guidance for the diagnosis and management of metabolic dysfunction-associated steatotic liver disease (MASLD)

YILMAZ Y., Adali G., Ergenc I., Kaya E., TURAN GÖKÇE D., KEKLİKKIRAN Ç., et al.
Hepatology Forum , cilt.7, sa.3, ss.177-214, 2026 (Scopus) Creative Commons License

5. Comparison of MELD, MELD-Na, and MELD 3.0 scoring systems for transplant prioritization in the turkish population: A multicenter study

Moral K., Harputluoğlu M., Özkumur G. F., Gavcar D., Erbay E., EREN F., et al.
Liver Transplantation , cilt.Publish Ahead of Print, 2026 (SCI-Expanded, Scopus)

6. De Novo Malignancies after Liver Transplantation: A Multicenter Cohort Study of Incidence, Timing, and Outcomes

DANIŞ N., DÖNGELLİ H., ÜNEK T., Bacakoğlu A., Turan İ., Karasu A. Z., et al.
The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology , cilt.37, sa.4, ss.510-523, 2026 (SCI-Expanded, Scopus, TRDizin) Creative Commons License

7. Ten-Year Follow-Up After 96 Weeks Treatment With Peginterferon Plus Tenofovir in Hepatitis D (HIDIT-II): Improved Clinical Outcome After Combination Therapy

Yurdaydin C., Kahlhöfer J., Caruntu F. A., Yalcin K., GÜREL S., Akarca U. S., et al.
United European Gastroenterology Journal , cilt.14, sa.1, 2026 (SCI-Expanded, Scopus)

8. Liver Failure, Hepatic Encephalopathy, and Infection Contribute to Mortality Risk in a Global Cirrhosis Cohort

Bajaj J. S., Silvey S., Mullan A., Choudhury A., Wong F., George J., et al.
Clinical Gastroenterology and Hepatology , cilt.24, sa.2, ss.453, 2026 (SCI-Expanded, Scopus)

9. Machine Learning Models Using Hospital Admission Characteristics Do Not Optimally Predict Nosocomial Infection Development in a Global Cirrhosis Cohort

Silvey S., Choudhury A. K., Kamath P. S., Xie Q., Wong F., Hayes P. C., et al.
American Journal of Gastroenterology , 2026 (SCI-Expanded, Scopus)

10. Risk Factors for Primary Sclerosing Cholangitis Recurrence Following Liver Transplantation: A Multicenter Retrospective Analysis

Adali G., Acar S., Harputluoğlu M., YILMAZ T. U., KARAKAYALI H., Istemihan Z., et al.
Clinical Transplantation , cilt.40, sa.1, 2026 (SCI-Expanded, Scopus)

11. Declining but persistent hepatocellular cancer risk beyond 10 years of entecavir or tenofovir in chronic hepatitis B: Results from the PAGE-B cohort

Papatheodoridis G. V., Dalekos G., İDİLMAN R., Sypsa V., Buti M., Calleja J. L., et al.
Journal of Hepatology , 2026 (SCI-Expanded, Scopus)

12. Portal vein thrombosis increases short-term mortality among hospitalized patients with cirrhosis in a global cohort

Choudhury A., Silvey S., Wong F., Kamath P. S., George J., İDİLMAN R., et al.
Liver Transplantation , 2026 (SCI-Expanded, Scopus)

13. The Global ACLF Consensus : the ‘Istanbul Document’

Kulkarni A. V., Choudhury A., Arora V., Dokmeci A. K., Koshy A., Gurakar A., et al.
Hepatology International , 2026 (SCI-Expanded, Scopus) Creative Commons License

14. Chronic kidney disease in cirrhosis: a study of inpatients from a global perspective

Wong F., Adebayo D., George J., İDİLMAN R., Hayes P. C., Alvares-da-Silva M. R., et al.
Gut , 2026 (SCI-Expanded, Scopus)

15. Enhancement of Inpatient Mortality Prognostication With Machine Learning in a Prospective Global Cohort of Patients With Cirrhosis With External Validation

Silvey S., Kamath P. S., George J., Choudhury A., Xie Q., Topazian M., et al.
Gastroenterology , cilt.170, sa.1, ss.148-160, 2026 (SCI-Expanded, Scopus)

16. Pre-transplant predictors of 3-Month survival following liver transplantation for acute liver failure in adult and pediatric patients in Türkiye

Turan İ., Akarca U. S., Aladağ M., Harputluoğlu M., YILMAZ S., Gençdal G., et al.
Scientific Reports , cilt.15, sa.1, 2025 (SCI-Expanded, Scopus)

17. Histological disease progression in patients with metabolic dysfunction–associated steatotic liver disease using paired liver biopsy

Turan Gokce D., Ekelik M., Gumussoy M., Kiremitci S., Bodakci E., Yilmaz V., et al.
European Journal of Gastroenterology and Hepatology , 2025 (SCI-Expanded, Scopus)

18. The impact of long-term potent antiviral therapy on the natural course of disease in patients with hepatitis B virusrelated cirrhosis

Kilic G., Guvenir T., BODAKÇİ E., MELEKOĞLU ELLİK Z., GÖKCAN H., İDİLMAN R.
Hepatology Forum , cilt.6, sa.4, ss.141-145, 2025 (Scopus)

19. Efficacy and tolerability of tenofovir alafenamide fumarate prophylaxis in HBV-infected individuals receiving chemo/ immunosuppressive therapy

DİLBER F., DURAK S., DEMİR M., YILDIRIM A. E., MELEKOĞLU ELLİK Z., ADANIR H., et al.
Hepatology forum , 2025 (ESCI, Scopus, TRDizin)

20. Updates on Recent Advancements in Hepatitis D Virus Treatment

Bardak A. E., Ozturk N. B., Gurakar M., Sequeira L., Yildiz E., Ozmert E. H., et al.
Viruses , cilt.17, sa.8, 2025 (SCI-Expanded, Scopus)

21. Hepatic steatosis is associated with HBSAG seroclearance in patients with chronic hepatitis B virus infection but it is also associated with disease progression

Bodakçı E., KİREMİTCİ S., MELEKOĞLU ELLİK Z., Koç Ö., GÜMÜŞSOY M., YILMAZ V., et al.
Hepatology forum , 2025 (ESCI, Scopus, TRDizin)

22. Ornidazole-Induced Liver Injury: The Clinical Characterization of a Rare Adverse Reaction and Its Implications from a Multicenter Study

Çalışkan A. R., Turan I., Vatansever S., Weninger J., Şamdancı E. T., AKATLI A. N., et al.
Biomedicines , cilt.13, sa.7, 2025 (SCI-Expanded, Scopus)

23. Outcomes of Transjugular Intrahepatic Portosystemic Shunt Procedures in a Very-Low-Volume Institution: A Retrospective Single-Center Study

çelebioğlu E. C., ULUDAĞ S., İDİLMAN R., GÖKCAN H., ÜSTÜNER E., MELEKOĞLU ELLİK Z., et al.
Journal of Gastrointestinal and Abdominal Radiology , 2025 (Hakemli Dergi)

24. The efficacy of magnetic resonance elastography in predicting oesophageal varices in patients with chronic liver disease

Adigüzel M., ERDEN G. A., KURU ÖZ D., Bodakcı E., İDİLMAN R.
Polish Journal of Radiology , cilt.90, 2025 (ESCI, Scopus)

25. Mushroom Intoxication in Türkiye: A Nationwide Cohort Study Based on Demographic Trends, Seasonal Variations, and the Impact of Climate Change on Incidence

Gökçe D., Ari D., Ata N., GÖKCAN H., İDİLMAN R., Ülgü M. M., et al.
Turkish Journal of Gastroenterology , cilt.36, sa.1, ss.61-66, 2025 (SCI-Expanded, Scopus, TRDizin)

26. Global prevalence and characteristics of infections and clinical outcomes in hospitalised patients with cirrhosis: a prospective cohort study for the CLEARED Consortium

Cao Z., Wong F., Choudhury A. K., Kamath P. S., Topazian M., Torre A., et al.
The Lancet Gastroenterology and Hepatology , cilt.9, sa.11, ss.997-1009, 2024 (SCI-Expanded, Scopus)

27. Assessing hepatic steatosis by magnetic resonance in potential living liver donors

Kuru Öz D., Ellik Z., Gürsoy Çoruh A., Adıgüzel M., Gümüşsoy M., Kiremitci S., et al.
Diagnostic and Interventional Radiology , cilt.30, sa.6, ss.351-356, 2024 (SCI-Expanded, Scopus, TRDizin)

28. HEPATIC STEATOSIS IS ASSOCIATED WITH HBSAG CLEARANCE IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION

BODAKÇİ E., KİREMİTCİ S., DUMAN S., MELEKOĞLU ELLİK Z., Gumussoy M., GÜVENİR S. T., et al.
HEPATOLOGY , 2024 (SCI-Expanded, Scopus)

29. ASSESSMENT OF THE RELATIONSHIP BETWEEN MRI-BASED INTRAMUSCULAR FAT INDICATING SARCOPENIA IN VARIOUS MUSCLE GROUPS AMONG PATIENTS WITH CHRONIC LIVER DISEASE

Er R. E., Akkaya Z., Ünal S., Kuru Öz D., Çelebi M. M., Gökcan H., et al.
HEPATOLOGY , 2024 (SCI-Expanded, Scopus)

30. Changing Trends in the Etiology of Cirrhosis in Türkiye: A Multicenter Nationwide Study

Üçbilek E., Yıldırım A. E., Ellik Z., Turan İ., HAKTANIYAN B., Orucu B., et al.
Turkish Journal of Gastroenterology , cilt.35, sa.10, ss.772-777, 2024 (SCI-Expanded, Scopus, TRDizin)

31. HOSPITALIZED PATIENTS WITH CIRRHOSIS, ESPECIALLY THOSE NOT IN HIGH INCOME COUNTRIES CONTINUE TO HAVE WORSE OUTCOMES REGARDLESS OF WHETHER OUTCOMES WERE STUDIED DURING AND AFTER THE COVID PANDEMIC

Bajaj J., Xie Q., Kamath P. S., Topazian M., Hayes P. C., Torre Torre A., et al.
HEPATOLOGY , 2024 (SCI-Expanded, Scopus)

32. A Brief Communication of Patients of Patients with Homozygous C282Y Mutation-Related Hereditary Hemochromatosis.

GÖKCAN H., Öz d. K., BODAKÇİ E., İDİLMAN R.
Hepatology forum , cilt.5, ss.161-164, 2024 (ESCI, Scopus, TRDizin)

33. A brief communication of patients with homozygous C282Y mutation-related hereditary hemochromatosis

GÖKCAN H., Oz D., BODAKÇİ E., TUNÇ E., İDİLMAN R.
HEPATOLOGY FORUM , cilt.5, sa.3, ss.161-164, 2024 (ESCI, Scopus, TRDizin)

34. Histological and clinical disease progression in patients with metabolic dysfunction-associated steatotic liver disease using paired liver biopsy

Ekelik M., Gokce D. T., Gumussoy M., KİREMİTCİ S., Bodakci E., Yilmaz V., et al.
JOURNAL OF HEPATOLOGY , 2024 (SCI-Expanded, Scopus)

35. Recurrence of primary sclerosing cholangitis after living donor liver transplantation: experience from turkish registry

Adali G., Harputluoglu M., Kayhan M. A., Gokce D. T., AKARSU M., Daniscomma N., et al.
JOURNAL OF HEPATOLOGY , 2024 (SCI-Expanded, Scopus)

36. A combination of non-invasive tests for the detection of significant fibrosis in patients with metabolic dysfunction-associated steatotic liver disease is not superior to magnetic resonance elastography alone

Duman S., Kuru D., Gumussoy M., KİREMİTCİ S., GÖKCAN H., Ulas B., et al.
EUROPEAN RADIOLOGY , cilt.34, sa.6, ss.3882-3888, 2024 (SCI-Expanded, Scopus)

37. Patterns and predictors of postacute discharge location other than home in a global cohort of 3, 678 patients hospitalized with cirrhosis

Seto W., Xie Q., Choudhury A. K., Kamath P. S., Topazian M., Hayes P., et al.
JOURNAL OF HEPATOLOGY , 2024 (SCI-Expanded, Scopus)

38. Portal vein thrombosis increases short-term mortality independent of liver disease severity score among hospitalized patients of decompensated cirrhosis-result from CLEARED consortium

Choudhury A. K., Xie Q., Topazian M., Torre A., Hayes P., Desalegn H., et al.
JOURNAL OF HEPATOLOGY , 2024 (SCI-Expanded, Scopus)

39. Natural history of clinical outcomes and hepatic decompensation in metabolic dysfunction-associated steatotic liver disease

Noureddin N., Huang D. Q., Bettencourt R., Siddiqi H., Majzoub A. M., Nayfeh T., et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS , sa.12, ss.1521-1526, 2024 (SCI-Expanded, Scopus)

40. Chronic hepatitis delta with normal ALT and hepatitis D viremia: unravelling its natural history

Gulnar M. O., Kamal H., Palom A., Arici S., Esteban R., TUNÇ E., et al.
JOURNAL OF HEPATOLOGY , 2024 (SCI-Expanded, Scopus)

41. DISEASE PROGRESSION IN PATIENTS WITH METABOLIC DYSFUNCTIONASSOCIATED STEATOTIC LIVER DISEASE USING PAIRED LIVER BIOPSY

Turan D., Ekelik M. M., Gumussoy M., Kiremitci S., Bodakci E., Yilmaz V., et al.
GASTROENTEROLOGY , cilt.166, sa.5, ss.1642, 2024 (SCI-Expanded, Scopus)

42. Geographic disparities in access to liver transplant for advanced cirrhosis: Time to ring the alarm!

Bajaj J. S., Choudhury A., Kumaran V., Wong F., Seto W. K., Alvares-Da-Silva M. R., et al.
American Journal of Transplantation , cilt.24, sa.5, ss.733-742, 2024 (SCI-Expanded, Scopus)

43. A global action agenda for turning the tide on fatty liver disease

Lazarus J. V., Mark H. E., Allen A. M., Arab J. P., Carrieri P., Noureddin M., et al.
Hepatology , cilt.79, sa.2, ss.502-523, 2024 (SCI-Expanded, Scopus)

44. Five-year follow-up of 96 weeks peginterferon plus tenofovir disoproxil fumarate in hepatitis D

Anastasiou O. E., Caruntu F. A., Curescu M. G., Yalcin K., Akarca U. S., GÜREL S., et al.
Liver International , cilt.44, sa.1, ss.139-147, 2024 (SCI-Expanded, Scopus)

45. Low liver fat in non-alcoholic steatohepatitis-related significant fibrosis and cirrhosis is associated with hepatocellular carcinoma, decompensation and mortality.

Lee S. W., Huang D. Q., Bettencourt R., Ajmera V., Tincopa M., Noureddin N., et al.
Alimentary pharmacology & therapeutics , cilt.59, sa.1, ss.80-88, 2024 (SCI-Expanded, Scopus)

46. Changing trends in the etiology of liver transplantation in Turkiye: A multicenter study

Akarsu M., DOLU S., Harputluoglu M., YILMAZ S., Akyildiz M., Gencdal G., et al.
HEPATOLOGY FORUM , cilt.5, sa.1, ss.3-6, 2024 (ESCI, Scopus) Creative Commons License Sürdürülebilir Kalkınma

47. Demonstration of therapy response to radioembolization with 90Y resin microspheres on 68Ga-PSMA PET/MRI in a patient with hepatocellular carcinoma

Özkan E., Demir B., Kuru Öz D., Soydal Ç., Dursun E., Çelebioğlu E. C., et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING , cilt.51, sa.1, ss.316-317, 2023 (SCI-Expanded, Scopus)

48. Magnetic resonance elastography-based prediction model for hepatic decompensation in NAFLD: A multicenter cohort study.

Kim B. K., Bergstrom J., Loomba R., Tamaki N., Izumi N., Nakajima A., et al.
Hepatology (Baltimore, Md.) , cilt.78, sa.6, ss.1858-1866, 2023 (SCI-Expanded, Scopus)

49. Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories.

Razavi-Shearer D., Child H., Razavi-Shearer K., Voeller A., Razavi H., Buti M., et al.
Journal of hepatology , 2023 (SCI-Expanded, Scopus)

50. MEFIB-Index and MAST-Score in the assessment of hepatic decompensation in metabolic dysfunction-associated steatosis liver disease-Individual participant data meta-analyses.

Noureddin N., Ajmera V., Bergstrom J., Bettencourt R., Huang D. Q., Siddiqi H., et al.
Alimentary pharmacology & therapeutics , cilt.58, sa.9, ss.856-865, 2023 (SCI-Expanded, Scopus)

51. A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease

Romero-Gómez M., Lawitz E., Shankar R. R., Chaudhri E., Liu J., Lam R. L., et al.
Journal of Hepatology , cilt.79, sa.4, ss.888-897, 2023 (SCI-Expanded, Scopus)

52. Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis.

Huang D. Q., Noureddin N., Ajmera V., Amangurbanova M., Bettencourt R., Truong E., et al.
The lancet. Gastroenterology & hepatology , cilt.8, sa.9, ss.829-836, 2023 (SCI-Expanded, Scopus)

53. Quality-of-life scores improve after 96 weeks of PEG-IFNa-2a treatment of hepatitis D: An analysis of the HIDIT-II trial

Dinkelborg K., Kahlhöfer J., Dörge P., Yurdaydin C., Hardtke S., Caruntu F. A., et al.
Liver International , cilt.43, sa.8, ss.1663-1676, 2023 (SCI-Expanded, Scopus)

54. Global disparities in mortality and liver transplantation in hospitalised patients with cirrhosis: a prospective cohort study for the CLEARED Consortium

Bajaj J. S., Choudhury A. K., Xie Q., Kamath P. S., Topazian M., Hayes P. C., et al.
The Lancet Gastroenterology and Hepatology , cilt.8, sa.7, ss.611-622, 2023 (SCI-Expanded, Scopus)

55. Identification of risk factors for alcohol relapse in liver transplant patients with alcohol-related liver disease

Turan D., GÜNŞAR F., Harputluoglu M., Kabacam G., Gokcan H., Akyildiz M., et al.
JOURNAL OF HEPATOLOGY , cilt.78, 2023 (SCI-Expanded, Scopus)

56. Stratification of liver fat content in non-alcoholic steatohepatitis patients with significant liver fibrosis using the MEFIB-Index and MRI-PDFF and its association with hepatocellular carcinoma, decompensation, and mortality

Lee S. W., Huang D., Ajmera V., Tincopa M., Bergstrom J., Noureddin N., et al.
JOURNAL OF HEPATOLOGY , cilt.78, 2023 (SCI-Expanded, Scopus)

57. Nosocomial infections in cirrhosis are unpredictable and vary based on region of the world: CLEARED study

Bajaj J. S., Wong F., Xie Q., Kamath P. S., Topazian M., Sarin S. K., et al.
JOURNAL OF HEPATOLOGY , cilt.78, 2023 (SCI-Expanded, Scopus)

58. Five years follow-up of 96 weeks peginterferon plus tenofovir disoproxil fumarate in hepatitis D

Anastasiou O. A., Caruntu F. A., Curescu M. G., YALÇIN K., AKARCA U. S., GÜREL S., et al.
JOURNAL OF HEPATOLOGY , cilt.78, 2023 (SCI-Expanded, Scopus)

59. Availability and affordability of services affects outcome in hospitalized patients with cirrhosis-results from CLEARED consortium

Choudhury A., Xie Q., Topazian M., Sarin S. K., Hayes P., Torre A., et al.
JOURNAL OF HEPATOLOGY , cilt.78, 2023 (SCI-Expanded, Scopus)

60. Development of metabolic disorders in transplant recipients

Erdemir G., GÖKCAN H., GÜRSOY ÇORUH A., GÜLPINAR B., Ellik Z., Gumussoy M., et al.
JOURNAL OF HEPATOLOGY , cilt.78, 2023 (SCI-Expanded, Scopus)

61. The role of PAGE-B score in predicting the development of hepatocelular cancer in patients with chronic delta hepatitis

KESKİN O., Kalkan C., ÖZTÜRK B., Caliskan A., Sahin H., Gumussoy M., et al.
JOURNAL OF HEPATOLOGY , cilt.78, 2023 (SCI-Expanded, Scopus)

62. Non-invasive fibrosis markers for assessment of liver fibrosis in chronic hepatitis delta

Kalkan Ç., Yılmaz Y., Erdoğan B. D., SAVAŞ B., Yurdcu E., Çalışkan A., et al.
Journal of Viral Hepatitis , cilt.30, sa.5, ss.406-416, 2023 (SCI-Expanded, Scopus)

63. TASL Practice Guidance on the Clinical Assessment and Management of Patients with Nonalcoholic Fatty Liver Disease.

YILMAZ Y., ZEYBEL M., ADALI G., COŞAR A., SERTESEN E., SÜMER H., et al.
Hepatology forum , cilt.4, sa.Suppl 1, ss.1-32, 2023 (ESCI, TRDizin) Creative Commons License

64. Determining Subclinical Cardiovascular and Cardiac Diseases in Patients with Non-Alcoholic Fatty Liver Disease

Karaoğlan B. B., Tulunay C., Uzun Ç., Peker E., Özyüncü N., Ellik Z., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.34, sa.3, ss.242-253, 2023 (SCI-Expanded, Scopus, TRDizin) Creative Commons License

65. Management of Biliary Complications in Liver Transplant Recipients with Duct-To-Duct Anastomosis: A Single-Center Experience

Karakaya M. F., Er E., Kırımker O., Gümüşsoy M., Bodakçi E., Özercan M., et al.
The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology , cilt.34, sa.2, ss.177-181, 2023 (SCI-Expanded, Scopus, TRDizin)

66. The efficacy and tolerability of glecaprevir/pibrentasvir treatment in a real-world chronic hepatitis C patients cohort

Yaras S., Demir M., Barutcu S., Yildirim A. E., GÜREL S., Ucbilek E., et al.
Hepatology Forum , cilt.4, sa.3, ss.92-96, 2023 (Scopus)

67. Diagnosis and Treatment of Autoimmune Hepatitis: Questions, Answers, and Illustrative Cases: Endorsed by Autoimmune Liver Diseases Special Interest Group, Turkish Association for the Study of Liver

Özaslan E., Günşar F., ÇİFCİBAŞI ÖRMECİ A., Hatemi İ., Efe C., AKYOL G., et al.
Turkish Journal of Gastroenterology , cilt.34, 2023 (SCI-Expanded, Scopus, TRDizin)

68. Liver injury after SARS-CoV-2 vaccination: Features of immune-mediated hepatitis, role of corticosteroid therapy and outcome

Efe C., Kulkarni A. V., Terziroli Beretta-Piccoli B., Magro B., Stättermayer A., Cengiz M., et al.
Hepatology , cilt.76, sa.6, ss.1576-1586, 2022 (SCI-Expanded, Scopus)

69. Factors associated with the development of extrahepatic malignancy in patients with nonalcoholic fatty liver disease: a single-center longitudinal study

Gumussoy M., Koc O., KARATAŞ G., Ozercan M., Ellik Z., DUMAN S., et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY , cilt.34, sa.11, ss.1172-1177, 2022 (SCI-Expanded, Scopus)

70. LOW SERUM ALBUMIN AT ADMISSION IS ASSOCIATED WITH MORTALITY AMONG INPATIENTS WITH CIRRHOSIS: A MULTI-NATIONAL EXPERIENCE

Wong F., Choudhury A. K., Xie Q., İDİLMAN R., George J., Kouacou M. J. D. L. E., et al.
HEPATOLOGY , cilt.76, 2022 (SCI-Expanded, Scopus)

71. DIFFERENCES IN MORTALITY RATES IN INPATIENTS WITH CIRRHOSIS DEPENDS ON THE LOW, MIDDLE OR HIGH INCOME COUNTRY LOCATION: MULTI-NATIONAL CLEARED CONSORTIUM EXPERIENCE

Bajaj J. S., Wong F., Xie Q., Topazian M., Aldo T., İDİLMAN R., et al.
HEPATOLOGY , cilt.76, 2022 (SCI-Expanded, Scopus)

72. NATURAL DISEASE OUTCOMES IN PATIENT WITH NONALCOHOLIC FATTY LIVER DISEASE: A STUDY WITH PAIRED LIVER BIOPSIES

Gumussoy M., Gokce D., Ekelik M., KİREMİTCİ S., Bodakci E., DUMAN S., et al.
HEPATOLOGY , cilt.76, 2022 (SCI-Expanded, Scopus)

73. Liver Stiffness on Magnetic Resonance Elastography and the MEFIB Index and Liver-Related Outcomes in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Individual Participants.

Ajmera V., Kim B. K., Yang K., Majzoub A. M., Nayfeh T., Tamaki N., et al.
Gastroenterology , cilt.163, sa.4, ss.1079, 2022 (SCI-Expanded, Scopus)

74. EFFECT OF PROGNOSTIC NONINVASIVE TESTS ON DISEASE OUTCOME OF ALCOHOL-RELATED LIVER DISEASE

Zengin B. A., Gumussoy M., Duman S., Bodakçi E., Güvenir S. T., Ellik Z., et al.
HEPATOLOGY , 2022 (SCI-Expanded, Scopus)

75. Liver fibrosis and its response to avapritinib in 2 patients with systemic mastocytosis

Cavazos K., Eswaran S., Maidlow C., KEKLİK KARADAĞ F., İDİLMAN R., İDİLMAN İ. S., et al.
BLOOD ADVANCES , cilt.6, sa.20, ss.5630-5633, 2022 (SCI-Expanded, Scopus) Creative Commons License

76. SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis

Efe C., Taşçılar K., Gerussi A., Bolis F., Lammert C., Ebik B., et al.
Journal of Autoimmunity , cilt.132, 2022 (SCI-Expanded, Scopus)

77. FUNCTIONAL CURE WITH LONAFARNIB-BASED THERAPY IN CHRONIC HEPATITIS DELTA

Yurdaydin C., Yurdcu E., Gumussoy M., KESKİN O., Gencdal G., Akyildiz M., et al.
HEPATOLOGY , cilt.76, 2022 (SCI-Expanded, Scopus)

78. MEFIB AND MAST SCORES ASSESSMENT OF INCIDENT LIVER-RELATED OUTCOMES IN NONALCOHOLIC FATTY LIVER DISEASE: AN INDIVIDUAL PATIENT META-ANALYSIS

Noureddin N., Ajmera V., Bergstrom J., Huang D., Siddiqi H., Majzoub A., et al.
HEPATOLOGY , cilt.76, 2022 (SCI-Expanded, Scopus)

79. Eliminating Viral Hepatitis in Turkey: Achievements and Challenges

AKARCA U. S., BAYKAM N., GÜNER H. R., GÜNŞAR F., İDİLMAN R., Kaymakoglu S., et al.
VIRAL HEPATIT DERGISI-VIRAL HEPATITIS JOURNAL , cilt.28, sa.2, ss.14-21, 2022 (ESCI, TRDizin) Creative Commons License

80. NSAID-associated drug-induced liver injury prior to and following liver transplantation

Gumussoy M., GÖKCAN H., BODAKÇİ E., KİREMİTCİ S., SAVAŞ B., İDİLMAN R.
HEPATOLOGY FORUM , cilt.3, sa.3, ss.108-109, 2022 (ESCI)

81. Characteristics of patients with hepatocellular carcinoma: A multicenter study

Guzelbulut F., KARAOĞULLARINDAN Ü., AKKIZ H., ALTINTAŞ E., DEMİRTAŞ C. Ö., Bahadir O., et al.
HEPATOLOGY FORUM , cilt.3, sa.3, ss.71-76, 2022 (ESCI, Scopus, TRDizin) Creative Commons License

82. Chronic hepatitis delta with normal ALT and hepatitis D viremia

Arici S., Palom A., Gumussoy M., İDİLMAN R., Gencdal G., Esteban R., et al.
JOURNAL OF HEPATOLOGY , cilt.77, 2022 (SCI-Expanded, Scopus)

83. The course of COVID-19 infection in patients with chronic hepatitis B and Delta

PARLAR Y. E., KESKİN O., KIRMIZIGÜL B., Gencdal G., Zeybel M., Gumussoy M., et al.
JOURNAL OF HEPATOLOGY , cilt.77, 2022 (SCI-Expanded, Scopus)

84. Liver stiffness on magnetic resonance elastography and liver-related outcomes in nonalcoholic fatty liver disease: a systematic review and meta-analysis of individual participants

Ajmera V., Yang K., Kim B. K., Majzoub A., Tamaki N., Nakajima A., et al.
JOURNAL OF HEPATOLOGY , cilt.77, 2022 (SCI-Expanded, Scopus)

85. Effectiveness of MRI methods in the assessment of hepatic steatosis in living liver donors

KURU ÖZ D., Ellik Z. M., Coruh A. G., ADIGÜZEL M., Gumussoy M., DUMAN S., et al.
JOURNAL OF HEPATOLOGY , cilt.77, 2022 (SCI-Expanded, Scopus)

86. A phase 2 dose-finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis

Yurdaydin C., Keskin O., Yurdcu E., Caliskan A., Onem S., Karakaya F., et al.
HEPATOLOGY , cilt.75, sa.6, ss.1551-1565, 2022 (SCI-Expanded, Scopus)

87. Global multi-stakeholder endorsement of the MAFLD definition

Méndez-Sánchez N., Bugianesi E., Gish R. G., Lammert F., Tilg H., Nguyen M. H., et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY , cilt.7, sa.5, ss.388-390, 2022 (SCI-Expanded, Scopus)

88. Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis

Efe C., Lammert C., Taşçılar K., Dhanasekaran R., Ebik B., Higuera-de la Tijera F., et al.
Liver International , cilt.42, sa.3, ss.607-614, 2022 (SCI-Expanded, Scopus) Creative Commons License

89. An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B

Kim H. Y., Lampertico P., Nam J. Y., Lee H., Kim S. U., Sinn D. H., et al.
JOURNAL OF HEPATOLOGY , cilt.76, sa.2, ss.311-318, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

90. Evaluation of Magnetic Resonance Elastography and Transient Elastography for Liver Fibrosis and Steatosis Assessments in the Liver Transplant Setting

Ellik Z., İDİLMAN İ. S., Kartal A., Balaban Y., ELHAN A. H., KARÇAALTINCABA M., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.33, sa.2, ss.153-160, 2022 (SCI-Expanded, Scopus, TRDizin)

91. Advancing the global public health agenda for NAFLD: a consensus statement

Lazarus J. V., Mark H. E., Anstee Q. M., Arab J. P., Batterham R. L., Castera L., et al.
Nature Reviews Gastroenterology and Hepatology , cilt.19, sa.1, ss.60-78, 2022 (SCI-Expanded, SSCI, Scopus) Creative Commons License

92. Determination of Turkish norms of psychometric tests for diagnosing minimal hepatic encephalopathy and proposal of a high sensitive screening test battery

ÖZBAŞ B., Keskin O., Hecker H., Karahan I., ÖZBAŞ C., Kalkan C., et al.
HEPATOLOGY INTERNATIONAL , cilt.15, ss.1442-1455, 2021 (SCI-Expanded, Scopus)

93. Characteristics of Newly Diagnosed Hepatocellular Carcinoma Patients Across Turkey: Prospective Multicenter Observational 3K Registry Study

AKARCA U. S., Unsal B., Sezgin O., Yalcin K., Akdogan M., Gonen C., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.32, sa.12, ss.1019-1028, 2021 (SCI-Expanded, Scopus, TRDizin)

94. Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients With Chronic Hepatitis B

Jang H., Yoon J. S., Park S. Y., Lee H. A., Jang M., Kim S. U., et al.
Clinical Gastroenterology and Hepatology , cilt.74, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

95. HBV/HDV management after liver transplantation: Review

Muhammad H., Zaffar D., Tehreem A., Peng-Sheng T., ŞİMŞEK C., GÖKCAN H., et al.
Journal of Liver Transplantation , 2021 (Hakemli Dergi)

96. Recommendations for Hepatitis B Immunoglobulin and Antiviral Prophylaxis Against Hepatitis B Recurrence After Liver Transplantation

AKARSU M., Onem S., TURAN İ., Adali G., Akdogan M., Akyildiz M., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.32, sa.9, ss.712-719, 2021 (SCI-Expanded, Scopus, TRDizin) Sürdürülebilir Kalkınma

97. The feasibility of T2 mapping in the assessment of hepatic steatosis, inflammation, and fibrosis in patients with non-alcoholic fatty liver disease: a preliminary study.

Idilman I. S., Celik A., Savas B., Idilman R., Karcaaltincaba M.
Clinical radiology , cilt.76, sa.9, 2021 (SCI-Expanded, Scopus)

98. Hepatitis D Infection in Asia: A Perspective From an Endemic Region

GÖKCAN H., İDİLMAN R.
Clinical Liver Disease , cilt.18, sa.1, ss.26-29, 2021 (Scopus) Sürdürülebilir Kalkınma

99. Association between non-alcoholic fatty liver disease and extrahepatic malignancy

Gumussoy M., İDİLMAN R., GÖKCAN H., Gokce D., Ulas B. B., Koc O., et al.
JOURNAL OF HEPATOLOGY , cilt.75, 2021 (SCI-Expanded, Scopus)

100. Covid-19 in Liver Transplant Recipients: A National Cohort

Kabacam G., TURAN İ., KIYICI M., Ellik Z., DOLU S., Dayangac M., et al.
JOURNAL OF HEPATOLOGY , cilt.75, 2021 (SCI-Expanded, Scopus)

101. Etiology of Cirrhosis in Turkey: A National Cohort Study

YILDIRIM A. E., ÜÇBİLEK E., Oruncu M. B., TURAN İ., DEMİR M., Koksal A., et al.
JOURNAL OF HEPATOLOGY , cilt.75, 2021 (SCI-Expanded, Scopus)

102. The artificial intelligence-driven model for prediction of hepatocellular carcinoma development in chronic hepatitis B patients: Derivation and validation using 11, 111 patients from Asian and Caucasian cohorts

Kim H. Y., Lampertico P., Nam J. Y., Lee H., Kim S. U., Jang E. S., et al.
JOURNAL OF HEPATOLOGY , cilt.75, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

103. Outcomes and characteristics of hepatocellular carcinomas (HCC) in Caucasian chronic hepatitis B (CHB) patients treated with long-term entecavir (ETV) or tenofovir disoproxil fumarate (TDF) therapy

Papatheodoridis G., Dalekos G., İDİLMAN R., Sypsa V., Buti M., Calleja Panero J. L., et al.
JOURNAL OF HEPATOLOGY , cilt.75, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

104. Natural History of Cirrhosis: Changing Trends in Etiology Over the Years

İDİLMAN R., Aydogan M., Oruncu M. B., Kartal A., ELHAN A. H., Ellik Z., et al.
DIGESTIVE DISEASES , cilt.39, sa.4, ss.358-365, 2021 (SCI-Expanded, Scopus)

105. Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B

Papatheodoridis G., Dalekos G. N., İDİLMAN R., Sypsa V., Van Boemmel F., Buti M., et al.
JHEP REPORTS , cilt.3, sa.3, 2021 (ESCI, Scopus) Creative Commons License Sürdürülebilir Kalkınma

106. Outcome of COVID-19 in Patients With Autoimmune Hepatitis: An International Multicenter Study

Efe C., Dhanasekaran R., Lammert C., Ebik B., Higuera-de la Tijera F., Aloman C., et al.
HEPATOLOGY , cilt.73, sa.6, ss.2099-2109, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

107. Residual low HDV viraemia is associated HDV RNA relapse after PEG-IFNa-based antiviral treatment of hepatitis delta: Results from the HIDIT-II study

Bremer B., Anastasiou O. E., Hardtke S., Caruntu F. A., Curescu M. G., YALÇIN K., et al.
LIVER INTERNATIONAL , cilt.41, sa.2, ss.295-299, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

108. ATA Index: A novel score for predicting fibrosis stage in chronic viral hepatitis

Tugsal H. Y., YÜKSEL S., Kabacam G., Evirgen S., Akan K., AKYÜZ F., et al.
HEPATOLOGY FORUM , sa.1, ss.12-19, 2021 (ESCI) Creative Commons License

109. Clinical significance of concomitant extrahepatic autoimmune disease in patients with autoimmune liver disease

KARAKAYA M. F., USTA Ş., ÖZTÜRK Y., KALKAN Ç., MELEKOĞLU ELLİK Z., ELHAN A. H., et al.
Hepatology Forum , cilt.1, sa.2, ss.3-6, 2021 (ESCI)

110. Immunoglobulin light chain amyloidosis presenting as Budd-Chiari syndrome

Ozercan M., Eser I., KİREMİTCİ S., PEYNİRCİOĞLU B., Karayalcin S., İDİLMAN R.
Hepatology Forum , cilt.2, sa.3, ss.120-121, 2021 (Scopus)

111. MRI quantification techniques in fatty liver: the diagnostic performance of hepatic T1, T2, and stiffness measurements in relation to the proton density fat fraction

Erden A., KURU ÖZ D., PEKER E., Kul M., Ates F. S. O., Erden I., et al.
DIAGNOSTIC AND INTERVENTIONAL RADIOLOGY , cilt.27, sa.1, ss.7-14, 2021 (SCI-Expanded, Scopus, TRDizin)

112. The Prevalence of Metabolic Associated Fatty Liver Disease in The Turkish Population: A Multicenter Study

YILMAZ Y., YILMAZ N., ATEŞ F., KARAKAYA M. F., GÖKCAN H., KAYA E., et al.
Hepatology forum , cilt.2, sa.2, ss.37-42, 2021 (ESCI, Scopus)

113. Hepatitis D virus and liver transplantation: Indications and outcomes

Muhammad H., Tehreem A., Hammami M. B., Ting P., Idilman R., Gurakar A.
WORLD JOURNAL OF HEPATOLOGY , cilt.13, sa.3, ss.291-299, 2021 (ESCI, Scopus)

114. Real-world efficacy and safety of Ledipasvir plus Sofosbuvir and Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvir combination therapies for chronic hepatitis C: A Turkish experience

Degertekin B., DEMİR M., AKARCA U. S., Kani H. T., ÜÇBİLEK E., Yildirim E., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.31, sa.12, ss.883-893, 2020 (SCI-Expanded, Scopus, TRDizin)

115. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis

Fan R., Papatheodoridis G., Sun J., Innes H., Toyoda H., Xie Q., et al.
JOURNAL OF HEPATOLOGY , cilt.73, sa.6, ss.1368-1378, 2020 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma

116. Ten-year follow-up of a randomized controlled clinical trial in chronic hepatitis delta

Wranke A., Hardtke S., Heidrich B., Dalekos G., YALÇIN K., Tabak F., et al.
JOURNAL OF VIRAL HEPATITIS , cilt.27, sa.12, ss.1359-1368, 2020 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma

117. Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B

Papatheodoridis G., Dalekos G. N., İDİLMAN R., Sypsa V., Van Boemmel F., Buti M., et al.
JOURNAL OF HEPATOLOGY , cilt.73, sa.5, ss.1037-1045, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

118. Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B

Papatheodoridis G. V., Sypsa V., Dalekos G. N., Yurdaydin C., Van Boemmel F., Buti M., et al.
JOURNAL OF HEPATOLOGY , cilt.72, sa.6, ss.1088-1096, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

119. The COVID-19 pandemic: Clinical practice advice for gastroenterologists, hepatologists, and liver transplant specialists

Kabacam G., Dayangac M., ÜÇBİLEK E., Ercin C. N., Gunsar F., Akyilchz M., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.31, sa.5, ss.348-355, 2020 (SCI-Expanded, Scopus, TRDizin) Creative Commons License Sürdürülebilir Kalkınma

120. A micro-elimination approach to addressing hepatitis C in Turkey

İDİLMAN R., Razavi H., Robbins-Scott S., AKARCA U. S., Ormeci N., Kaymakoglu S., et al.
BMC HEALTH SERVICES RESEARCH , cilt.20, sa.1, 2020 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma

121. Metabolomics and microbial composition increase insight into the impact of dietary differences in cirrhosis

Cox I. J., İDİLMAN R., Fagan A., Turan D., Ajayi L., Le Guennec A. D., et al.
LIVER INTERNATIONAL , sa.2, ss.416-427, 2020 (SCI-Expanded, Scopus)

122. A rare disease that presents with acute severe hepatitis: Kikuchi-Fujimoto disease

ÇALIŞKAN KARTAL A., İDİLMAN R., MELEKOĞLU ELLİK Z., SAĞLAM A., CİVRİZ BOZDAĞ S.
Hepatology forum , cilt.1, ss.41-42, 2020 (Scopus)

123. The role of PNPLA3 (rs738409) cg variant on histological progression of non-alcoholic fatty liver disease

İDİLMAN R., ÖZEN KARATAYLI S. C., KABAÇAM G., SAVAŞ B., ELHAN A. H., BOZDAYI A. M.
Hepatology Forum , cilt.1, sa.3, ss.82-87, 2020 (ESCI, TRDizin) Creative Commons License

124. The natural course of non-alcoholic fatty liver disease

Cengiz Seval G., Kabaçam G., Yakut M., Seven G., Savaş B., Elhan A. H., et al.
Hepatology Forum , cilt.1, sa.1, ss.20-24, 2020 (ESCI, TRDizin) Creative Commons License

125. Low recurrence rate of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment in a real-world chronic hepatitis C patients cohort

İDİLMAN R., DEMİR M., ALADAĞ M., Erol C., Cavus B., Iliaz R., et al.
JOURNAL OF VIRAL HEPATITIS , cilt.26, sa.6, ss.666-674, 2019 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

126. Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial

Wedemeyer H., Yurdaydin C., Hardtke S., Caruntu F. A., Curescu M. G., YALÇIN K., et al.
LANCET INFECTIOUS DISEASES , cilt.19, sa.3, ss.275-286, 2019 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

127. Hepatitis B Reactivation Rate and Fate Among Multiple Myeloma Patients Receiving Regimens Containing Lenalidomide and/or Bortezomib

Atilla P. A., Yalciner M., Atilla E., İDİLMAN R., BEKSAÇ M.
TURKISH JOURNAL OF HEMATOLOGY , cilt.36, sa.4, ss.266-273, 2019 (SCI-Expanded, Scopus, TRDizin) Creative Commons License Sürdürülebilir Kalkınma

128. Long-term follow-up of patients treated with entecavir and peginterferon add-on therapy for HBeAg-positive chronic hepatitis B infection: ARES long-term follow-up

van Campenhout M. J. H., Brouwer W. P., Xie Q., Guo S., Chi H., Qi X., et al.
JOURNAL OF VIRAL HEPATITIS , cilt.26, sa.1, ss.109-117, 2019 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

129. Health-related Quality of Life of Liver Donors: A Prospective Longitudinal Study

Hesimov I., Kirimker E. O., Duman B., Keskin O., ÇETİNKAYA Ö. A., Hayme S., et al.
TRANSPLANTATION PROCEEDINGS , cilt.50, sa.10, ss.3076-3081, 2018 (SCI-Expanded, Scopus)

130. Viral dominance patterns in chronic hepatitis delta determine early response to interferon alpha therapy

Lutterkort G. L., Wranke A., Hengst J., Yurdaydin C., Stift J., Bremer B., et al.
JOURNAL OF VIRAL HEPATITIS , cilt.25, sa.11, ss.1384-1394, 2018 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

131. Serum biomarkers for the evaluation of liver fibrosis: The need for better tests

Zeybel M., İDİLMAN R.
TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.29, sa.4, ss.377-378, 2018 (SCI-Expanded, Scopus, TRDizin) Creative Commons License

132. Diet affects gut microbiota and modulates hospitalization risk differentially in an international cirrhosis cohort

Bajaj J. S., İDİLMAN R., Mabudian L., Hood M., Fagan A., Turan D., et al.
HEPATOLOGY , sa.1, ss.234-247, 2018 (SCI-Expanded, Scopus)

133. Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population

Papatheodoridis G. V., Sypsa V., Dalekos G., Yurdaydin C., van Boemmel F., Buti M., et al.
JOURNAL OF HEPATOLOGY , cilt.68, sa.6, ss.1129-1136, 2018 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

134. Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV-1 study

Yurdaydin C., Keskin O., Kalkan C., Karakaya F., Caliskan A., Karatayli E., et al.
HEPATOLOGY , sa.4, ss.1224-1236, 2018 (SCI-Expanded, Scopus)

135. Interferon Treatment Duration in Patients With Chronic Delta Hepatitis and its Effect on the Natural Course of the Disease

Yurdaydin C., Keskin O., Kalkan C., Karakaya F., Caliskan A., Kabacam G., et al.
JOURNAL OF INFECTIOUS DISEASES , sa.8, ss.1184-1192, 2018 (SCI-Expanded, Scopus) Creative Commons License

136. Diagnosis, management and treatment of hepatitis B virus infection: Turkey 2017 Clinical Practice Guidelines

TABAK Ö. F., Yurdaydin C., KAYMAKOĞLU S., Tabak F., Akarsu M., Akinci E. G., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.28, 2017 (SCI-Expanded, Scopus, TRDizin)

137. Diagnosis, management and treatment of hepatitis delta virus infection: Turkey 2017 Clinical Practice Guidelines

Yurdaydin C., Tabak F., KAYMAKOĞLU S., TABAK Ö. F., Akarsu M., Akinci E. G., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.28, 2017 (SCI-Expanded, Scopus, TRDizin)

138. Recommendation for treatment of hepatitis C virus infection

KAYMAKOĞLU S., Koksal I., KAYMAKOĞLU S., Tabak F., AKARCA U. S., Akbulut A., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.28, 2017 (SCI-Expanded, Scopus, TRDizin)

139. Turkey 2017 Clinical Practice Guidelines on recommendations for screning diagnosing and managing hepatitis C virus

Idilman R., Baykam N., KAYMAKOĞLU S., Tabak F., Bahcecioglu H. I., Bektas A., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.28, 2017 (SCI-Expanded, Scopus, TRDizin)

140. The Risk of Hepatocellular Carcinoma Decreases After the First 5 Years of Entecavir or Tenofovir in Caucasians With Chronic Hepatitis B

Papatheodoridis G. V., İDİLMAN R., Dalekos G. N., Buti M., Chi H., van Boemmel F., et al.
HEPATOLOGY , cilt.66, sa.5, ss.1444-1453, 2017 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

141. Management of special patient groups with hepatitis B virus infection: The EASL 2017 Clinical Practice Guidelines

İDİLMAN R.
TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.28, sa.6, ss.518-521, 2017 (SCI-Expanded, Scopus, TRDizin) Sürdürülebilir Kalkınma

142. The summarized of EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

İDİLMAN R.
TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.28, sa.5, ss.412-416, 2017 (SCI-Expanded, Scopus, TRDizin) Sürdürülebilir Kalkınma

143. Pharmacokinetics and Pharmacodynamics Modeling of Lonafarnib in Patients With Chronic Hepatitis Delta Virus Infection

Canini L., Koh C., Cotler S. J., Uprichard S. L., Winters M. A., Han M. A. T., et al.
HEPATOLOGY COMMUNICATIONS , cilt.1, sa.4, ss.288-292, 2017 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

144. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study

Blach S., Zeuzem S., Manns M., Altraif I., Duberg A., Muljono D. H., et al.
The Lancet Gastroenterology and Hepatology , cilt.2, sa.3, ss.161-176, 2017 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma

145. Non-invasive fibrosis score for hepatitis delta

Lutterkort G. L., Wranke A., Yurdaydin C., Budde E., Westphal M., Lichtinghagen R., et al.
LIVER INTERNATIONAL , cilt.37, sa.2, ss.196-204, 2017 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

146. Discontinuation of lamivudine treatment in HBeAg-negative chronic hepatitis B: a pilot study with long-term follow-up

Karakaya F., Ozer S., Kalkan C., Tuzun E. A., Caliskan A., Keskin O., et al.
ANTIVIRAL THERAPY , sa.7, ss.559-570, 2017 (SCI-Expanded, Scopus)

147. Daclatasvir Plus Asunaprevir Dual Therapy for Chronic HCV Genotype 1b Infection: Results of Turkish Early Access Program

Koklu S., Koksal I., AKARCA U. S., BALKAN A., Guner R., Demirezen A., et al.
ANNALS OF HEPATOLOGY , cilt.16, sa.1, ss.71-76, 2017 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

148. Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B

Marcellin P., Ahn S. H., Chuang W. -., Hui A. J., TABAK Ö. F., Mehta R., et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS , cilt.44, sa.9, ss.957-966, 2016 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

149. The long-term efficacy of combining nucleos(t)ide analog and low-dose hepatitis B immunoglobulin on post-transplant hepatitis B virus recurrence

İDİLMAN R., Akyildiz M., Keskin O., Gungor G., Yilmaz T. U., Kalkan C., et al.
CLINICAL TRANSPLANTATION , cilt.30, sa.10, ss.1216-1221, 2016 (SCI-Expanded, Scopus)

150. Stone-containing Cystic Mass at the Portal Hilus of the Liver in an Asymptomatic Young Female Patient Duplication of the Gallbladder

İDİLMAN R., Erden A., Karakaya F.
GASTROENTEROLOGY , sa.2, 2016 (SCI-Expanded, Scopus) Creative Commons License

151. Comparison of survival, safety, and efficacy after transarterial chemoembolization and radioembolization of Barcelona Clinic Liver Cancer stage B-C hepatocellular cancer patients

SOYDAL Ç., Arslan M. F., KÜÇÜK N. Ö., İDİLMAN R., Bilgic S.
NUCLEAR MEDICINE COMMUNICATIONS , cilt.37, sa.6, ss.646-649, 2016 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

152. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy

Papatheodoridis G., Dalekos G., Sypsa V., Yurdaydin C., Buti M., Goulis J., et al.
JOURNAL OF HEPATOLOGY , cilt.64, sa.4, ss.800-806, 2016 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

153. A comparison of liver fat content as determined by magnetic resonance imaging-proton density fat fraction and MRS versus liver histology in non-alcoholic fatty liver disease

İDİLMAN İ. S., Keskin O., Celik A., SAVAŞ B., ELHAN A. H., İDİLMAN R., et al.
ACTA RADIOLOGICA , cilt.57, sa.3, ss.271-278, 2016 (SCI-Expanded, Scopus)

154. Latest updates on chronic viral hepatitis B

İDİLMAN R., Karakaya F.
MARMARA MEDICAL JOURNAL , cilt.29, ss.33-37, 2016 (ESCI, Scopus, TRDizin) Creative Commons License Sürdürülebilir Kalkınma

155. Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome

Keskin O., Wedemeyer H., Tuzun A., Zachou K., Deda X., Dalekos G. N., et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY , cilt.13, sa.13, ss.2342-2351, 2015 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

156. Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial

Koh C., Canini L., Dahari H., Zhao X., Uprichard S. L., Haynes-Williams V., et al.
LANCET INFECTIOUS DISEASES , cilt.15, sa.10, ss.1167-1174, 2015 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma

157. Sequential development of acute autoimmune hepatitis may lead to a serious clinical picture in primary biliary cirrhosis

Keskin O., İDİLMAN R.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY , cilt.27, sa.10, ss.1228-1229, 2015 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

158. Therapy of Delta Hepatitis

Yurdaydin C., İDİLMAN R.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE , cilt.5, sa.10, 2015 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma

159. Quantification of liver, pancreas, kidney, and vertebral body MRI-PDFF in non-alcoholic fatty liver disease

İDİLMAN İ. S., Tuzun A., SAVAŞ B., ELHAN A. H., Celik A., İDİLMAN R., et al.
ABDOMINAL IMAGING , cilt.40, sa.6, ss.1512-1519, 2015 (SCI-Expanded, Scopus)

160. Prognostic factors for prediction of survival of hepatocellular cancer patients after selective internal radiation therapy

SOYDAL Ç., Keskin O., KÜÇÜK N. Ö., ÖZKAN E., Bilgic S., İDİLMAN R., et al.
ANNALS OF NUCLEAR MEDICINE , cilt.29, sa.5, ss.426-430, 2015 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

161. Adding Pegylated Interferon to Entecavir for Hepatitis B e Antigen-Positive Chronic Hepatitis B: A Multicenter Randomized Trial (ARES Study)

Brouwer W. P., Xie Q., Sonneveld M. J., Zhang N., Zhang Q., TABAK Ö. F., et al.
HEPATOLOGY , cilt.61, sa.5, ss.1512-1522, 2015 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

162. Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naive chronic hepatitis B patients in the real-world setting

Idilman R., Gunsar F., Koruk M., Keskin O., Meral C. E., Gulsen M., et al.
JOURNAL OF VIRAL HEPATITIS , cilt.22, sa.5, ss.504-510, 2015 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

163. Interleukin-28 gene polymorphisms may contribute to HBsAg persistence and the development of HBeAg-negative chronic hepatitis B

Karatayli S. C., Bozdayi M., Karatayli E., ÖZTÜRK T., Husseini A. A., ALBAYRAK DELİALİOĞLU R., et al.
LIVER INTERNATIONAL , cilt.35, sa.3, ss.846-853, 2015 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

164. Nonalcoholic fatty liver disease is associated with significant coronary artery disease in type 2 diabetic patients: A computed tomography angiography study

İdilman R., Akata D., Hazırolan T., Doğanay B., Aytemir K., Karçaaltıncaba M.
JOURNAL OF DIABETES , cilt.7, sa.2, ss.279-286, 2015 (SCI-Expanded, Scopus)

165. Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir

Papatheodoridis G. V., Dalekos G. N., Yurdaydin C., Buti M., Goulis J., Arends P., et al.
JOURNAL OF HEPATOLOGY , cilt.62, sa.2, ss.363-370, 2015 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

166. A potential link between endothelial function, cardiovascular risk, and metabolic syndrome in patients with Non-alcoholic fatty liver disease

Arslan M. S., Turhan S., Dinçer İ., Mizrak D., Çorapçıoğlu D., İdilman R.
DIABETOLOGY & METABOLIC SYNDROME , cilt.6, 2014 (SCI-Expanded, Scopus) Creative Commons License

167. Role of immunohistochemistry for hepatitis D and hepatitis B virus in hepatitis delta

Kabacam G., Wedemeyer H., SAVAŞ B., Keskin O., Dalekos G., TABAK Ö. F., et al.
LIVER INTERNATIONAL , cilt.34, sa.8, ss.1207-1215, 2014 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

168. Hepatitis C virus genotype distribution in Turkey remains unchanged after a decade: Performance of phylogenetic analysis of the NS5B, E1, and 5 ' UTR regions in genotyping efficiency

Alagoz G. K., Karatayli S. C., Karatayli E., Celik E., Keskin O., Dinc B., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.25, sa.4, ss.405-410, 2014 (SCI-Expanded, Scopus, TRDizin) Sürdürülebilir Kalkınma

169. Public awareness of hepatitis B infection in Turkey as a model of universal effectiveness in health care policy

Gurakar M., Malik M., Keskin O., İDİLMAN R.
TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.25, sa.3, ss.304-308, 2014 (SCI-Expanded, Scopus, TRDizin) Sürdürülebilir Kalkınma

170. Impact of sequential proton density fat fraction for quantification of hepatic steatosis in nonalcoholic fatty liver disease

Idilman I. S., Keskin O., ELHAN A. H., Idilman R., KARÇAALTINCABA M.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY , cilt.49, sa.5, ss.617-624, 2014 (SCI-Expanded, Scopus)

171. A one step real time PCR method for the quantification of hepatitis delta virus RNA using an external armored RNA standard and intrinsic internal control

Karatayli E., Altunoglu Y. C., Karatayli S. C., Alagoz S. G. K., ÇINAR K., YALÇIN K., et al.
JOURNAL OF CLINICAL VIROLOGY , cilt.60, sa.1, ss.11-15, 2014 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

172. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm

Razavi H., Waked I., Sarrazin C., Myers R. P., Idilman R., Calinas F., et al.
JOURNAL OF VIRAL HEPATITIS , cilt.21, ss.34-59, 2014 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

173. Strategies to manage hepatitis C virus (HCV) disease burden

Wedemeyer H., Duberg A. S., Buti M., Rosenberg W. M., Frankova S., Esmat G., et al.
JOURNAL OF VIRAL HEPATITIS , cilt.21, ss.60-89, 2014 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

174. Historical epidemiology of hepatitis C virus (HCV) in selected countries

Bruggmann P., Berg T., Ovrehus A. L. H., Moreno C., Brandao Mello C. E., Roudot-Thoraval F., et al.
JOURNAL OF VIRAL HEPATITIS , cilt.21, ss.5-33, 2014 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

175. Tumour necrosis factor-alpha, interleukin-10, interferon-gamma and vitamin D receptor gene polymorphisms in patients with chronic hepatitis delta

Karatayli S. C., Ulger Z. E., Ergul A. A., Keskin O., Karatayli E., Albayrak R., et al.
JOURNAL OF VIRAL HEPATITIS , cilt.21, sa.4, ss.297-304, 2014 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

176. Endoscopic treatment of biliary complications following liver transplantation

Seven G., ÇINAR K., İDİLMAN R., TÜZÜNER A., Hazinedaroglu S. M., Karayalcin S., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.25, sa.2, ss.156-161, 2014 (SCI-Expanded, Scopus, TRDizin)

177. Manometric assessment of esophageal motor function in patients with primary biliary cirrhosis

Bektas M., Seven G., İDİLMAN R., Yakut M., DOĞANAY ERDOĞAN B., Kabacam G., et al.
EUROPEAN JOURNAL OF INTERNAL MEDICINE , cilt.25, sa.3, ss.230-234, 2014 (SCI-Expanded, Scopus)

178. Efficacy of tenofovir in adefovir-experienced patients compared with treatment-naive patients with chronic hepatitis B

Keskin O., Ormeci A. C., Baran B., Kabacam G., Tuzun A., Karatayli E., et al.
ANTIVIRAL THERAPY , cilt.19, sa.6, ss.543-550, 2014 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

179. Vanishing bile duct syndrome after allogeneic bone marrow transplantation: Is it the end of the road?

Bakanay S. M., Ugur Bilgin A., Bektas M., İDİLMAN R., Erden E., Arat M., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.24, sa.4, ss.359-362, 2013 (SCI-Expanded, Scopus, TRDizin)

180. Hepatic Steatosis: Quantification by Proton Density Fat Fraction with MR Imaging versus Liver Biopsy

İDİLMAN İ. S., Aniktar H., İDİLMAN R., Kabacam G., SAVAŞ B., ELHAN A. H., et al.
RADIOLOGY , cilt.267, sa.3, ss.767-775, 2013 (SCI-Expanded, Scopus)

181. Kidney transplantation from hepatitis B (HB)-positive donors to HB negative recipients: anti-HB Core immunoglobulin G became positive in all recipients after the transplantation.

Celebi Z. K., Sengul Ş., Soypacaci Z., Yayar O., Idilman R., Tuzuner A., et al.
Transplantation proceedings , cilt.45, sa.3, ss.923-5, 2013 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

182. Clonal analysis of the quasispecies of antiviralresistant HBV genomes in patients with entecavir resistance during rescue treatment and successful treatment of entecavir resistance with tenofovir

Karatayli E., İDİLMAN R., Karatayli S. C., Cevik E., Yakut M., Seven G., et al.
Antiviral Therapy , cilt.18, sa.1, ss.77-85, 2013 (SCI-Expanded, Scopus)

183. Using chimeric mice with humanized livers to predict human drug metabolism and a drug-drug interactions

Nishimura T., Hu Y., Wu M., Pham E., Suemizu H., Elazar M., et al.
Journal of Pharmacology and Experimental Therapeutics , cilt.344, sa.2, ss.388-396, 2013 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma

184. The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country

Toy M., ÖNDER F. O., İDİLMAN R., Kabacam G., Richardus J. H., Bozdayi M., et al.
EUROPEAN JOURNAL OF HEALTH ECONOMICS , cilt.13, sa.5, ss.663-676, 2012 (SSCI, Scopus) Creative Commons License Sürdürülebilir Kalkınma

185. HBeAg-positive hepatitis delta: Virological patterns and clinical long-term outcome

Heidrich B., C. Serrano B., İDİLMAN R., Kabaçam G., Bremer B., Raupach R., et al.
Liver International , cilt.32, sa.9, ss.1415-1425, 2012 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

186. Entecavir treatment of chronic hepatitis D

Kabaçam G., Önder F. O., Yakut M., Seven G., Karatayli S. C., Karatayli E., et al.
Clinical Infectious Diseases , cilt.55, sa.5, ss.645-650, 2012 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

187. Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients

Idilman R., Cinar K., Seven G., Bozkus Y., ELHAN A. H., Bozdayi M., et al.
JOURNAL OF VIRAL HEPATITIS , cilt.19, sa.3, ss.220-226, 2012 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

188. Potential proteomic biomarkers in assessing liver fibrosis using SELDI-TOF MS

Karatayli S. C., Alagöz S. G., Mizrak D., Sayki M., Özkan M., SAVAŞ B., et al.
Turkish Journal of Gastroenterology , cilt.23, sa.1, ss.46-53, 2012 (SCI-Expanded, Scopus, TRDizin) Sürdürülebilir Kalkınma

189. Molecular characterization of a novel entecavir mutation pattern isolated from a multi-drug refractory patient with chronic hepatitis B infection

Karatayli E., Karatayli S. C., ÇINAR K., GÖKAHMETOĞLU S., GÜVEN K., İDİLMAN R., et al.
Journal of Clinical Virology , cilt.53, sa.2, ss.130-134, 2012 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

190. Hepatic encephalopathy

Yurdaydin C., İDİLMAN R.
European Gastroenterology and Hepatology Review , cilt.7, sa.4, ss.268-271, 2012 (Scopus)

191. Assessment of Helicobacter pylori eradication rate of triple combination therapy containing levofloxacin

Seven G., ÇINAR K., Yakut M., İDİLMAN R., Özden A.
Turkish Journal of Gastroenterology , cilt.22, sa.6, ss.582-586, 2011 (SCI-Expanded, Scopus, TRDizin)

192. Complete genome sequences and phylogenetic analysis of hepatitis delta viruses isolated from nine Turkish patients

Çelik I., Karatayli E., Çevik E., Gökçe Kabakçi S., Karatayli S. C., Dinç B., et al.
Archives of Virology , cilt.156, sa.12, ss.2215-2220, 2011 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

193. Evaluation and management of hepatitis B virus infection in hematopoietic stem cell transplantation: Before and after transplantation

İDİLMAN R., Arat M.
Expert Review of Anti-Infective Therapy , cilt.9, sa.8, ss.641-652, 2011 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

194. Gamma-glutamyltranspeptidase in predicting sustained virological response in individuals with chronic hepatitis C

Çoban Ş., İDİLMAN R., Erden E., Tuz̈un̈ A.
Hepato-Gastroenterology , cilt.58, sa.109, ss.1301-1306, 2011 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

195. Lymphoproliferative Disorders in Individuals With Chronic Hepatitis B and C in the Turkish Population

İDİLMAN R., Bozkus Y., CENGİZ SEVAL G., Mizrak D., ÇINAR K., Ustun Y., et al.
JOURNAL OF MEDICAL VIROLOGY , cilt.83, sa.6, ss.974-980, 2011 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

196. Natural history and treatment of chronic delta hepatitis.

Yurdaydin C., Idilman R., Bozkaya H., Bozdayi A.
Journal of viral hepatitis , cilt.17, sa.11, ss.749-56, 2010 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

197. MR angiography of esophageal mural veins in portal hypertension: a correlation with endoscopic grades of esophageal varices.

Erden A., İDİLMAN R., Erden I., Bektaş M., Özden A.
The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology , cilt.21, sa.3, ss.275-9, 2010 (SCI-Expanded, Scopus, TRDizin)

198. The Characteristics and Clinical Outcome of Drug-induced Liver Injury A Single-center Experience

İDİLMAN R., Bektas M., Cinar K., TÖRÜNER M., Cerit E. T., DOĞANAY ERDOĞAN B., et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY , cilt.44, sa.6, 2010 (SCI-Expanded, Scopus)

199. Endoscopic management of biliary parasitic diseases

Bektaş M., Dökmeci A., ÇINAR K., Halici I., Oztas E., Karayalcin S., et al.
Digestive Diseases and Sciences , cilt.55, sa.5, ss.1472-1478, 2010 (SCI-Expanded, Scopus)

200. Gastric aberrant pancreas

Mizrak D., Bektaş M., KAYGUSUZ G., ÇINAR K., İDİLMAN R., Özden A.
Turkish Journal of Gastroenterology , cilt.21, sa.1, ss.68-69, 2010 (SCI-Expanded, Scopus, TRDizin)

201. Aflatoxin exposure in viral hepatitis patients in Turkey

Mizrak D., Engin B., ÖNDER F. O., Yener B., Bektas M., Biyikli Z., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.20, sa.3, ss.192-197, 2009 (SCI-Expanded, Scopus, TRDizin) Sürdürülebilir Kalkınma

202. A short course of add-on adefovir dipivoxil treatment in lamivudine-resistant chronic hepatitis B patients

İDİLMAN R., Kaymakoglu S., Oguz Onder F., Ahishali E., Bektas M., ÇINAR K., et al.
Journal of Viral Hepatitis , cilt.16, sa.4, ss.279-285, 2009 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

203. Awareness of the endoscopist affects detection rate of heterotopic gastric mucosa in esophagus

Korkut E., Bektas M., SAVAŞ B., Memmedzade F., Öztas E., Üstün Y., et al.
Indian Journal of Gastroenterology , cilt.28, sa.2, ss.75-76, 2009 (Scopus)

204. Veins around the esophagus and the stomach: Do their calibrations provide a diagnostic clue for portal hypertensive gastropathy?

Erden A., İDİLMAN R., Erden I., Ozden A.
CLINICAL IMAGING , cilt.33, sa.1, ss.22-24, 2009 (SCI-Expanded, Scopus)

205. PPAR-alpha L162V polymorphism in human hepatocellular carcinoma

Koytak E. S., Mizrak D., Bektas M., Verdi H., ARSLAN ERGÜL A., Idilman R., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.19, sa.4, ss.245-249, 2008 (SCI-Expanded, Scopus, TRDizin) Sürdürülebilir Kalkınma

206. Hepatic complications of allogeneic hematopoietic cell transplantation

İDİLMAN R., Arat M.
Turkish Journal of Hematology , cilt.25, sa.3, ss.111-123, 2008 (SCI-Expanded, Scopus, TRDizin) Sürdürülebilir Kalkınma

207. Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis

Idilman R., Mizrak D., Corapcioglu D., Bektas M., Doganay B., Sayki M., et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS , cilt.28, sa.2, ss.200-208, 2008 (SCI-Expanded, Scopus)

208. Adjuvant therapeutic plasma exchange in liver failure - Assessments of clinical and laboratory parameters

Bektas M., İDİLMAN R., Soykan I., Soydan E., Arat M., ÇINAR K., et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY , cilt.42, sa.5, ss.517-521, 2008 (SCI-Expanded, Scopus)

209. P wave dispersion is prolonged in patients with Wilson's disease

Arat N., Kacar S., Golbasi Z., Akdogan M., Sokmen Y., Kuran S., et al.
WORLD JOURNAL OF GASTROENTEROLOGY , cilt.14, sa.8, ss.1252-1256, 2008 (SCI-Expanded, Scopus)

210. Hydatid cysts in muscle: a modified percutaneous treatment approach

Ormeci N., Idilman R., Akyar S., Palabiylkoglu M., Coban S., Erdem H., et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES , cilt.11, sa.3, ss.204-208, 2007 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma

211. The fate of recipient-derived hepatocytes in sex-mismatched liver allograft following liver transplantation

Idilman R., Erden E., KUZU I., Ersoz S., Karayalcin S.
CLINICAL TRANSPLANTATION , cilt.21, sa.2, ss.202-206, 2007 (SCI-Expanded, Scopus)

212. Antituberculous therapy-induced fulminant hepatic failure: Successful treatment with liver transplantation and nonstandard antituberculous therapy

Idilman R., Ersoz S., Coban S., Kumbasar Z., Bozkaya H.
LIVER TRANSPLANTATION , cilt.12, sa.9, ss.1427-1430, 2006 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

213. A case of systemic lupus erythematosus presenting with protein-losing enteropathy

Türkçapar N., ÖZYÜNCÜ N., ÇINAR K., ENSARİ A., KÜÇÜK N. Ö., İDİLMAN R., et al.
Turkish Journal of Gastroenterology , cilt.17, sa.3, ss.226-230, 2006 (SCI-Expanded, Scopus, TRDizin)

214. Duration of lamivudine prophylaxis in inactive hepatitis B virus carriers with haemato/oncological malignancies who receive chemotherapy

Idilman R.
GUT , cilt.55, sa.8, ss.1208-1209, 2006 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

215. Hepatitis B core antigen expression pattern reflects the response to anti-viral treatment

Uzun Y., Bozkaya H., Erden E., Cinar K., Idilman R., Yurdaydin C., et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY , cilt.21, sa.6, ss.977-981, 2006 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

216. Macro-amylasemia in a patient with selective IgA deficiency and antiphospholipid antibodies

Türkçapar N., ÖZYÜNCÜ N., İDİLMAN R., ENSARİ A., Soylu K., Özden A.
Turkish Journal of Gastroenterology , cilt.17, sa.2, ss.140-143, 2006 (SCI-Expanded, Scopus, TRDizin) Sürdürülebilir Kalkınma

217. Anti-viral prophylaxis in inactive hepatitis B virus carriers with hemato-oncological malignancies who receive chemotherapy

İDİLMAN R.
Minerva Gastroenterologica e Dietologica , cilt.52, sa.1, ss.39-45, 2006 (Scopus) Sürdürülebilir Kalkınma

218. Long-term prognosis of nonalcoholic fatty liver disease: Is pharmacological therapy actually necessary?

Cinar K., Coban S., Idilman R., Tuzun A., Sarioglu M., Bektas M., et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY , cilt.21, sa.1, ss.169-173, 2006 (SCI-Expanded, Scopus)

219. Evaluation of the effect of transplant-related factors and tissue injury on donor-derived hepatocyte and gastrointestinal epithelial cell repopulation following hematopoietic cell transplantation

Idilman R., KUZU I., Erden E., Arat M., Soydan E., Soykan I., et al.
BONE MARROW TRANSPLANTATION , cilt.37, sa.2, ss.199-206, 2006 (SCI-Expanded, Scopus) Creative Commons License

220. Intestinal B cell lymphoma associated with chronic hepatitis C and celiac disease

Coban S., Palabiyikoglu M., ENSARİ A., Idilman R., Koklu S., Yolcu O., et al.
DIGESTIVE DISEASES AND SCIENCES , cilt.50, sa.12, ss.2359-2361, 2005 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

221. Ursodeoxycholic acid treatment in isolated chronic graft-vs.-host disease of the liver

Arat M., Idilman R., Soydan E., Soykan I., Erden E., Karayalcin S., et al.
CLINICAL TRANSPLANTATION , cilt.19, sa.6, ss.798-803, 2005 (SCI-Expanded, Scopus)

222. Peroxisome proliferator-activated receptor alpha L162V polymorphism in nonalcoholic steatohepatitis and genotype 1 hepatitis C virus-related liver steatosis

Verdi H., Koytak E., Onder O., Cinar K., Idilman R., Erden E., et al.
JOURNAL OF INVESTIGATIVE MEDICINE , cilt.53, sa.7, ss.353-359, 2005 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

223. Trefoil factor expression graft-versus-host disease of in biliary epithelium of the liver after allogeneic hematopoietic cell transplantation

Idilman R., Erden E., Arat M., Soydan E., Erkan O., KUZU I., et al.
TRANSPLANTATION , cilt.80, sa.8, ss.1099-1104, 2005 (SCI-Expanded, Scopus)

224. A new percutaneous approach for the treatment of hydatid cyst of the kidney: Long-term follow-up

Ormeci N., Idilman R., Tuzun A., Erdem H., Palabiyikoglu M.
INTERNATIONAL UROLOGY AND NEPHROLOGY , cilt.37, sa.3, ss.461-464, 2005 (SCI-Expanded, Scopus)

225. Complete genome sequence and phylogenetic analysis of hepatitis B virus isolated from Turkish patients with chronic HBV infection

Bozdayi G., Turkyilmaz A., Idilman R., Karatayli E., Rota S., Yurdaydin C., et al.
JOURNAL OF MEDICAL VIROLOGY , cilt.76, sa.4, ss.476-481, 2005 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

226. Lamivudine prophylaxis in HBV carriers with haemato-oncological malignancies who receive chemotherapy

Idilman R.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY , cilt.55, sa.6, ss.828-831, 2005 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma

227. An unusual presentation of helicobacter pylori infection: So-called "Russell body gastritis"

ENSARİ A., Savas B., Heper A., KUZU I., Idilman R.
Virchows Archiv , cilt.446, sa.4, ss.463-466, 2005 (SCI-Expanded, Scopus)

228. Sexual dysfunctions in HCV patients and its correlations with psychological and biological variables

Soykan A., Boztas H., Idilman R., Ozel E. T., Tuzun A., Ozden A., et al.
INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH , cilt.17, sa.2, ss.175-179, 2005 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma

229. Lamivudine treatment in HBeAg-negative chronic hepatitis B patients with low level viraemia

Bozkaya H., Yurdaydin C., Idilman R., Tuzun A., Cinar K., Erkan O., et al.
ANTIVIRAL THERAPY , cilt.10, sa.2, ss.319-325, 2005 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

230. Recipient-derived hepatocytes in sex-mismatched liver allografts after liver transplantation: Early versus late transplant biopsies

Idilman R., Erden E., KUZU I., Ersoz S., KARASU A. Z., Karayalcin K., et al.
TRANSPLANTATION , cilt.78, sa.11, ss.1647-1652, 2004 (SCI-Expanded, Scopus)

231. Lymphoproliferative disorders in chronic hepatitis C

Idilman R., Colantoni A., De Maria N., Alkan S., Nand S., Van Thiel D.
JOURNAL OF VIRAL HEPATITIS , cilt.11, sa.4, ss.302-309, 2004 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

232. Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies

Idilman R., Arat M., Soydan E., TÖRÜNER M., Soykan I., Akbulut H., et al.
JOURNAL OF VIRAL HEPATITIS , cilt.11, sa.2, ss.141-147, 2004 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

233. Hepatitis B virus vaccination of recipients and donors of allogeneic peripheral blood stem cell transplantation.

Idilman R., Ustun C., Karayaicin S., Aktemel A., Turkyilmaz A., Ozcan M., et al.
Clinical transplantation , cilt.17, sa.5, ss.438-43, 2003 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

234. Hepatic apoptosis and proliferation in male and female rats fed alcohol: role of cytokines

Colantoni A., Idilman R., De Maria N., La Paglia N., Belmonte J., Wezeman F., et al.
ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH , cilt.27, sa.7, ss.1184-1189, 2003 (SCI-Expanded, Scopus)

235. Reversal of iron deficiency anemia in a patient with gastric antral vascular ectasia treated with cyproheptadine

Soykan I., TÖRÜNER M., Idilman R., Ozden A.
JOURNAL OF CLINICAL GASTROENTEROLOGY , cilt.36, sa.2, ss.183-184, 2003 (SCI-Expanded, Scopus)

236. Impaired antibody response rates after high dose short interval hepatitis B virus vaccination of immunosuppressed individuals

Idilman R., Colantoni A., De Maria N., Ustun C., Sam R., Ing T., et al.
HEPATO-GASTROENTEROLOGY , cilt.50, sa.49, ss.217-221, 2003 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

237. A new therapeutic approach for treatment of hydatid cysts of the spleen

Ormeci N., Soykan I., Palabiyikoglu M., Idilman R., Erdem H., Bektas A., et al.
DIGESTIVE DISEASES AND SCIENCES , cilt.47, sa.9, ss.2037-2044, 2002 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

238. Is pain experienced during liver biopsy an important factor?

Soykan I., TÖRÜNER M., Sarioglu M., Idilman R.
JOURNAL OF CLINICAL GASTROENTEROLOGY , cilt.35, sa.1, ss.102-103, 2002 (SCI-Expanded, Scopus)

239. Impaired response to high-dose interferon treatment in African-Americans with chronic hepatitis C.

De Maria N., Colantoni A., Idilman R., Friedlander L., Harig J., Van Thiel D. H.
Hepato-gastroenterology , cilt.49, sa.45, ss.788-92, 2002 (SCI-Expanded, Scopus)

240. Estrogen status and response to combination therapy for chronic hepatitis C

De Maria N., Colantoni A., Idilman R., Leone N., Villa E., Van Thiel D.
JOURNAL OF HEPATOLOGY , cilt.36, ss.233, 2002 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

241. The effect of high dose and short interval HBV vaccination in individuals with chronic hepatitis C

Idilman R., De Maria N., Colantoni A., Nadir A., Van Thiel D.
AMERICAN JOURNAL OF GASTROENTEROLOGY , cilt.97, sa.2, ss.435-439, 2002 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

242. Liver transplantation for fulminant hepatic failure

Van Thiel D., Brems J., Nadir A., Idilman R., Colantoni A., Holt D., et al.
JOURNAL OF GASTROENTEROLOGY , cilt.37, ss.78-81, 2002 (SCI-Expanded, Scopus) Creative Commons License

243. Bronchoalveolar lavage fluid analysis in individuals with chronic hepatitis C

Idilman R., Cetinkaya H., Savas I., Aslan N., SAK S., Bastemir M., et al.
JOURNAL OF MEDICAL VIROLOGY , cilt.66, sa.1, ss.34-39, 2002 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

244. Repopulation of liver endothelial cells, but not hepatocytes, by allogeneic hematopoietic cell transplants.

Idilman R., Tukun A., Erdem E., Arat M., TÖRÜNER M., Soykan I., et al.
BLOOD , cilt.98, sa.11, 2001 (SCI-Expanded, Scopus)

245. B-cell lymphoproliferative and plasma cell disorders in individuals with chronic hepatitis C.

Idilman R., Colantoni A., De Maria N., Alkan S., Nand S., Soykan I., et al.
HEPATOLOGY , cilt.34, sa.4, 2001 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

246. Increased effective immunogenicity to high-dose and short-interval hepatitis B virus vaccination in individuals with chronic hepatitis without cirrhosis

De Maria N., Idilman R., Colantoni A., Van Thiel D.
JOURNAL OF VIRAL HEPATITIS , cilt.8, sa.5, ss.372-376, 2001 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

247. Effect of human immunodeficiency virus on the outcome of hepatitis C virus infection

Idilman R., Colantoni A., De Maria N.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY , cilt.36, sa.3, ss.225-234, 2001 (SCI-Expanded, Scopus)

248. Evidence of oxidative injury during aging of the liver in a mouse model.

Colantoni A., Idilman R., de Maria N., Duffner L., Van Thiel D., Witte P., et al.
JOURNAL OF THE AMERICAN AGING ASSOCIATION , cilt.24, sa.2, ss.51-57, 2001 (SCI-Expanded, Scopus) Creative Commons License

249. The impact of previous HBV infection on the course of chronic hepatitis C

De Maria N., Colantoni A., Friedlander L., Leandro G., Idilman R., Harig J., et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY , cilt.95, sa.12, ss.3529-3536, 2000 (SCI-Expanded, Scopus)

250. Hepatitis B virus vaccination of recipients and donors of allogeneic peripheral blood stem cell transplantation: Risk and benefit ratio of HBV vaccination in recipients.

Idilman R., Ustun C., Akan H., Karayalcin S., Ozcan M., Arslan O., et al.
HEPATOLOGY , cilt.32, sa.4, 2000 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

251. Influence of sex hormonal status on alcohol-induced oxidative injury in male and female rat liver.

Colantoni A., La Paglia N., De Maria N., Emanuele M. A., Emanuele N. V., Idilman R., et al.
Alcoholism, clinical and experimental research , cilt.24, sa.9, ss.1467-73, 2000 (SCI-Expanded, Scopus)

252. Antibody response to hepatitis B virus vaccination in individuals with hepatitis C virus infection

De Maria N., Idilman R., Colantoni A., Harig J., Van Thiel D.
HEPATOLOGY , cilt.32, sa.2, ss.444, 2000 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

253. The response to interferon plus ribavirin re-treatment for chronic hepatitis C in interferon non-responders is not influenced by race

De Maria N., Colantoni A., Idilman R., Harig J., Van Thiel D.
JOURNAL OF HEPATOLOGY , cilt.33, sa.6, ss.1028-1029, 2000 (SCI-Expanded, Scopus)

254. Cirrhosis in Turner's syndrome: Case report and literature review

Idilman R., De Maria N., Colantoni A., Kugelmas M., Van Thiel D.
European Journal of Gastroenterology and Hepatology , cilt.12, sa.6, ss.707-709, 2000 (SCI-Expanded, Scopus)

255. The incidence of Hepatitis G virus in patients with hematological malignancies: The relationship to the number of blood and blood products transfusions

İDİLMAN R., Ustun C., Aslan O., ÖZCAN M. E., Arat M., Bozkaya H., et al.
Turkish Journal of Haematology , cilt.17, sa.2, ss.67-71, 2000 (SCI-Expanded, Scopus, TRDizin) Sürdürülebilir Kalkınma

256. Immunosuppressive therapy-induced hepatotoxicity in patients with aplastic anemia

Dilek I., İDİLMAN R., Fenkci S., Ustun C., KOÇ H., İLHAN O., et al.
Turkish Journal of Haematology , cilt.17, sa.3, ss.111-117, 2000 (SCI-Expanded, Scopus, TRDizin)

257. Adoptive immunity transfer in hepatitis B virus carriers with hematological malignancy who undergoing allogeneic hematopoietic stem cell transplantation

Idilman R., Ustun C., Turkyilmaz A., GÜRMAN G., Ozcan M., Karayalcin S., et al.
HEPATOLOGY , cilt.30, sa.4, 1999 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

258. Flow cytometric evaluation of cell counts in bronchoalveolar lavage fluid of patients with hepatitis C virus: As a predictive marker of idiopathic pulmonary fibrosis

Idilman R., Cetinkaya H., Savas I., Aslan N., Sarioglu M., Bozdayi M., et al.
HEPATOLOGY , cilt.30, sa.4, 1999 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

259. Hematopoietic stem cell transplantation from non-replicative hepatitis B virus carriers is safe

Ustun C., Idilman R., GÜRMAN G., Ozcan M., Akyol G., Akan H., et al.
JOURNAL OF HEPATOLOGY , cilt.31, sa.2, ss.202-209, 1999 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

260. Long term follow-up and late complications of 2-chlorodeoxyadenosine in previously treated, advanced, indolent non-Hodgkin's lymphoma

BEKSAÇ M., Idilman R.
CANCER , cilt.85, sa.1, ss.242-243, 1999 (SCI-Expanded, Scopus)

261. Is there any correlation between transfusion frequency of blood and blood products and blood-borne hepatitis virus transmission?

Idilman R., Ustun C., Bozkaya H., Bozdayi M., Akan H.
BLOOD , cilt.92, sa.10, 1998 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

262. Bronchoalveolar lavage fluid findings in patients with hepatitis C virus.

Cetinkava H., Idilman R., Savas I., Bastemir M., Karacan O., Sarioglu M., et al.
HEPATOLOGY , cilt.28, sa.4, 1998 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

263. Is there any correlation between transfusion frequency of blood and blood products and hepatitis G virus transmission.

Idilman R., Akan H., Ustun C., Bozkaya H., Bozdayi M., Uzunalimoglu O., et al.
HEPATOLOGY , cilt.28, sa.4, 1998 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

264. Which hematopoietic stem cell transplantation type is safe for patients with hepatitis B virus carriers.

Ustun C., Idilman R., Ozcan M., Akan H., Karayalcin S., GÜRMAN G., et al.
HEPATOLOGY , cilt.28, sa.4, 1998 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

265. Pathogenesis of hepatitis B and C-induced hepatocellular carcinoma

Idilman R., De Maria N., Colantoni A., Van Thiel D.
JOURNAL OF VIRAL HEPATITIS , cilt.5, sa.5, ss.285-299, 1998 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

266. Liver transplantation for chronic viral liver disease.

Colantoni A., Hassanein T., Idilman R., Van Thiel D. H.
Hepato-gastroenterology , cilt.45, sa.23, ss.1357-63, 1998 (SCI-Expanded, Scopus)

267. Cladribine therapy in chronic lymphoproliferative disorders: Single center experience

BEKSAÇ M., Ilhan O., Uysal A., Koc H., Idilman R., Arat M., et al.
BRITISH JOURNAL OF HAEMATOLOGY , cilt.102, sa.1, ss.244, 1998 (SCI-Expanded, Scopus)

268. Immunosuppressive drug-induced leukoencephalopathy in patients with liver transplant

Idilman R., De Maria N., Kugelmas M., Colantoni A., Van Thiel D.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY , cilt.10, sa.5, ss.433-436, 1998 (SCI-Expanded, Scopus)

269. Interferon treatment of HCV positive cirrhotic patients.

Idilman R., Colantoni A., De Maria N., Van Thiel D. H.
Hepato-gastroenterology , cilt.45, sa.20, ss.340-4, 1998 (SCI-Expanded, Scopus)

270. Fulminant hepatitis in aplastic anemia: hepatitis G or ALG?

Akan H., Konuk N., Fenkci S., Dilek I., Idilman R., Tuncer S.
BONE MARROW TRANSPLANTATION , cilt.21, sa.5, ss.533, 1998 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma

271. Current and future therapies for HCV infection: what should the end point for treatment be?

Van Thiel D. H., De Maria N., Colantoni A., Idilman R.
Hepato-gastroenterology , cilt.45, sa.20, ss.308-20, 1998 (SCI-Expanded, Scopus)

272. Donor leukocyte infusions for the treatment of leukemia relapse after allogeneic hematopoietic progenitor cell transplantation.

GÜRMAN G., Arslan O., Koc H., Dilek I., Ustun C., Ozcan M., et al.
BLOOD , cilt.90, sa.10, ss.4452, 1997 (SCI-Expanded, Scopus)

273. Polymerase chain reaction for the detection of HCV-RNA: cryoglobulinaemia as a cause for false negative results.

Colantoni A., De Maria N., Idilman R., Van Thiel D. H.
Italian journal of gastroenterology and hepatology , cilt.29, sa.3, ss.273-4, 1997 (SCI-Expanded)

274. Interferon treatment of cirrhotic patients with chronic hepatitis C

Idilman R., DeMaria N., Colantoni A., Dokmeci A., VanThiel D.
JOURNAL OF VIRAL HEPATITIS , cilt.4, sa.2, ss.81-91, 1997 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

275. Successful medical treatment of epithelioid hemangioendothelioma of liver

Idilman R., Dokmeci A., Beyler A., Bastemir M., Ormeci N., Aras N., et al.
ONCOLOGY , cilt.54, sa.2, ss.171-175, 1997 (SCI-Expanded, Scopus)

276. Hepatic osteodystrophy: A review

Idilman R., DeMaria N., Uzunalimoglu O., VanThiel D.
HEPATO-GASTROENTEROLOGY , cilt.44, sa.14, ss.574-581, 1997 (SCI-Expanded)

277. Protein C, protein S and antithrombin III levels in nephrotic syndrome.

Buyukberber S., Aydogdu I., Buyukberber N., Bektas A., Idilman R., Karatan O., et al.
BLOOD , cilt.88, sa.10, ss.2982, 1996 (SCI-Expanded, Scopus)
Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 197

1. Lonafarnib as finite treatment for chronic hepatitis D:Long-term effect on hard endpoints

YURTAYDIN S. C., ÖZARI GÜLNAR D. M., METİN R. O., TUNÇ E., KESKİN O., GÜMÜŞSOY M., et al.
EASL Congress, Barcelona, İspanya, 27 - 30 Mayıs 2026, cilt.84, ss.965-966, (Özet Bildiri)

2. Liver disease severity in index patients with matabolic dysfunction-associated steatotic liver disease predicts the disease in first-degree relatives: acall for targeted screening

TURAN GÖKÇE D., TUNÇ E., MELEKOĞLU ELLİK Z., GÜMÜŞSOY M., GÖKCAN H., İDİLMAN R.
EASL Congress, Barcelona, İspanya, 27 - 30 Mayıs 2026, cilt.84, ss.519-520, (Özet Bildiri)

3. Tek Merkez Delta Hepatit Veri Tabanının Medyan 10 Yıllık Takibinde, Hepatik Dekompansasyon, Kanser ve Ölüm Riski IFN, LNF Alan Hastalarda Hiç Tedavi Almayanlara Göre Daha Düşüktür ve Bunda 5 Yıldan Uzun Süreli NA Tedavisinin Etkisi Vardır

ÖZARI GÜLNAR D. M., TUNÇ E., MELEKOĞLU ELLİK Z., GÜMÜŞSOY M., GENÇDAL G., BOZDAYI A. M., et al.
17. ULUSAL HEPATOLOJİ KONGRESİ, Antalya, Türkiye, 14 - 17 Mayıs 2026, (Özet Bildiri)

4. Kronik Delta Hepatit'de Sınırlı Süreli Tedavi Yaklaşımı Olarak Lonafarnib'in Nihai Tedavi Sonlanım Noktarlarına Etkisi

YURTAYDIN S. C., TUNÇ E., KESKİN O., GÜMÜŞSOY M., BODAKÇİ E., GENÇDAL G., et al.
17. ULUSAL HEPATOLOJİ KONGRESİ, Antalya, Türkiye, 14 - 17 Mayıs 2026, (Özet Bildiri)

5. Alkol İlişkili Karaciğer Hastalığı Olan Hastalarda Non – İnvaziv Fibrozis Testlerinin Hastalık Sonuçlarını Öngörme Performansı

TURAN GÖKÇE D., MELEKOĞLU ELLİK Z., TUNÇ E., GÜMÜŞSOY M., GÖKCAN H., İDİLMAN R.
17. ULUSAL HEPATOLOJİ KONGRESİ, Antalya, Türkiye, 14 - 17 Mayıs 2026, (Özet Bildiri)

6. Etkili Tedavi Alan Kronik Hepatit D ve Kronik Hepatit B Hastalarında Hepatoselüler Karsinom Riski: Bir Eğilim Skoru

KESKİN O., ÖZARI GÜLNAR D. M., GÜMÜŞSOY M., TUNÇ E., MELEKOĞLU ELLİK Z., ZEYBEL M., et al.
17. ULUSAL HEPATOLOJİ KONGRESİ, Antalya, Türkiye, 14 - 17 Mayıs 2026, (Özet Bildiri)

7. Metabolik Disfonksiyonla İlişkili Yağlı Karaciğer Hastalığı (MASLD) Olan İndeks Hastalarda İleri Evre Fibrozis, Birinci Derece Akrabalardaki MASLD Riskini Güçlü Biçimde Öngörmektedir: Hedefe Yönelik Tarama İçin Bir Çağrı

TURAN GÖKÇE D., TUNÇ E., MELEKOĞLU ELLİK Z., GÜMÜŞSOY M., GÖKCAN H., İDİLMAN R.
17. ULUSAL HEPATOLOJİ KONGRESİ, Antalya, Türkiye, 14 - 17 Mayıs 2026, (Özet Bildiri)

8. PNPLA3 I148M Homozigot Mutasyonunun Hepatoselüler Kanser Hastalık Seyrine Etkisi

TURAN GÖKÇE D., TUNÇ E., MELEKOĞLU ELLİK Z., GÜMÜŞSOY M., ER R. E., GÖKCAN H., et al.
17. ULUSAL HEPATOLOJİ KONGRESİ, Antalya, Türkiye, 14 - 17 Mayıs 2026, (Özet Bildiri)

9. Superiority of the FAST score compared to traditional noninvasive indices in detecting liver fibrosis in asymptomatic patients with type 2 diabetes mellitus

ŞAHİN M., Unal F. T. S., MELEKOĞLU ELLİK Z., Yilmaz V., Oz D. K., GÖKCAN H., et al.
Congress of the European-Association-for-the-Study-of-the-Liver Congress (EASL), Barcelona, İspanya, 27 - 30 Mayıs 2026, cilt.84, (Özet Bildiri)

10. DOSE-SIZE RELATIONSHIP DEFINES LOCAL CONTROL AFTER LIVER SBRT: A QUANTITATIVE ANALYSIS OF BED10 AND LESION DIAMETER

Bayatfard P., Durmuş Z. B., UTKAN G., İDİLMAN R., KURU ÖZ D., DURU BİRGİ S., et al.
15TH INTERNATIONAL GASTROINTESTINAL CANCERS, Antalya, Türkiye, 04 Aralık 2025, (Tam Metin Bildiri)

11. A FUNCTIONAL CURE AFTER NUCLEOS(T)IDE ANALOGUE DISCONTINUATION IN NONCIRRHOTIC PATIENTS WITH HBEAGNEGATIVE CHRONIC HEPATITIS B

MELEKOĞLU ELLİK Z., Koç Ö., BODAKÇİ E., GÜMÜŞSOY M., ÖZERCAN A. M., YILMAZ V., et al.
AASLD 2025 congress, 7 - 11 Kasım 2025, (Tam Metin Bildiri)

12. COMPARISON OF MELD, MELDNA, AND MELD 3.0 SCORING SYSTEMS IN TRANSPLANT PRIORITIZATION IN THE TURKISH POPULATION: A MULTICENTER STUDY

moral k., Harputluoğlu M., ADANIR H., DANIŞ N., KIYICI M., Dayangaç M., et al.
AASLD 2025 congress, 07 Kasım 2025, (Tam Metin Bildiri)

13. The association of chronic kidney disaese with metabolic syndrome and perirenal adipose tissueliver transplant recipients

HATİPOĞLU S. N., GÖKCAN H., GÜRSOY ÇORUH A., kırkıcı b., MELEKOĞLU ELLİK Z., KOÇ Ö., et al.
AASLD 2025 congress, Washington, Kiribati, 7 - 11 Kasım 2025, (Tam Metin Bildiri)

14. ASSESSMENT OF THE RELATIONSHIP BETWEEN MRI-BASED INTRAMUSCULAR FAT INDICATING SARCOPENIA IN VARIOUS MUSCLE GROUPS AMONG PATIENTS WITH CHRONIC LIVER DISEASE

Er R. E., Akkaya Z., Ünal S., Kuru Öz D., Çelebi M. M., Gökcan H., et al.
AASLD Kongresi, California, Amerika Birleşik Devletleri, 11 - 15 Kasım 2024, ss.1701-1702, (Özet Bildiri)

15. NÖROENDOKRİN TÜMÖRDE ATİPİK GÖRÜNÜM: HİPERVASKÜLER OLMAYAN DİFFÜZ İNFİLTRATİF TİP KARACİĞER TUTULUMU

Yalçınkaya A. S., Tüten M. Z., Kuru Öz D., Gülpınar B., Erden G. A., İdilman R.
TÜRK MANYETİK REZONANS DERNEĞİ 29. YILLIK BİLİMSEL TOPLANTISI, Ankara, Türkiye, 1 - 03 Mayıs 2025, ss.78-79, (Özet Bildiri)

16. WIDE VARIATIONS IN ANTIMICROBIAL GENE CARRIAGE IN PATIENTS WITH CIRRHOSIS AND HEALTHY CONTROLS FROM 7 COUNTRIES WITH 1020 PARTICIPANTS: IMPLICATIONS FOR RESISTANT INFECTIONS

Bajaj J. S., Kupcinskas J., Kreivenaite E., Suk K. T., Sharma S., Lee H. W., et al.
Digestive Disease Week, California, Amerika Birleşik Devletleri, 3 - 06 Mayıs 2025, cilt.169, (Özet Bildiri)

17. Nucleosid analog cessation outcomes in noncirrhotic patients with HbeAg negative chronic hepatitit B

MELEKOĞLU ELLİK Z., Koç Ö., DUMAN S., GÜVENİR S. T., YILMAZ V., GÜMÜŞSOY M., et al.
EASL congress 2025, 7 - 10 Mayıs 2025, cilt.82, (Özet Bildiri)

18. Gut metagenomic profiles predict 90-day hospitalizations despite controlling for diet, demographics & cirrhosis details in a multi-country cohort of patients with cirrhosis

Bajaj J., Nikitina D., Sikaroodi M., Alvares-da-Silva M., Torre A., Suk K. T., et al.
European-Association-for-the-Study-of-the-Liver Congress, Amsterdam, Hollanda, 7 - 10 Mayıs 2025, cilt.82, (Özet Bildiri)

19. Outcomes beyond 10 years in entecavir or tenofovir treated Caucasian chronic hepatitis B patients of the real-life PAGE-B cohort

Papatheodoridis G., Dalekos G., İDİLMAN R., Sypsa V., Buti M., Panero J. L. C., et al.
European-Association-for-the-Study-of-the-Liver Congress, Amsterdam, Hollanda, 7 - 10 Mayıs 2025, cilt.82, (Özet Bildiri)

20. Nucleos(t)ide analogue cessation outcomes in non-cirrhotic patients with HBeAg-negative chronic hepatitis B

MELEKOĞLU ELLİK Z., ÜNAL F., Koc O., Duman S., Guvenir S. T., YILMAZ V., et al.
European-Association-for-the-Study-of-the-Liver Congress, Amsterdam, Hollanda, 7 - 10 Mayıs 2025, cilt.82, (Özet Bildiri)

21. HEPATIC STEATOSIS IS ASSOCIATED WITH HBSAG CLEARANCE IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION

BODAKÇİ E., KİREMİTCİ S., DUMAN S., MELEKOĞLU ELLİK Z., GÜMÜŞSOY M., GÜVENİR S. T., et al.
AASLD 2024 congress, 15 - 19 Kasım 2024, (Tam Metin Bildiri)

22. MAJOR VARIATIONS IN 90-DAY MORTALITY POST-HOSPITAL DISCHARGE AMONG INPATIENTS WITH CIRRHOSIS: A PROSPECTIVE COHORT STUDY FOR THE CLEARED CONSORTIUM

İDİLMAN R., HAKTANIYAN B., Choudhury A. K., Kamath P., Wong F., Alvares-da-Silva M., et al.
The Liver Meeting, California, Amerika Birleşik Devletleri, 15 - 19 Kasım 2024, (Özet Bildiri)

23. De novo malignancies after liver transplantation: multicenter study a preliminary report

Danis N., Akarsu M., Harputluoglu M., Yilmaz S., Adanir H., Dincer D., et al.
International Congress of the International-Liver-Transplantation-Society (ILTS), Texas, Amerika Birleşik Devletleri, 1 - 04 Mayıs 2024, ss.165-166, (Özet Bildiri)

24. CHRONIC HEPATITIS DELTA WITH NORMAL ALT AND HEPATITIS D VIREMIA: UNRAVELLING ITS NATURAL HISTORY

ÖZARI GÜLNAR D. M., TUNÇ E., KESKİN O., İDİLMAN R., YURTAYDIN S. C.
Meeting:European-Association-for-the-Study-of-the-Liver Congress (EASL), Milan, İtalya, 5 - 08 Haziran 2024, cilt.80, ss.785, (Özet Bildiri)

25. Wide variations in proton pump inhibitor use in hospitalized patients with cirrhosis in a worldwide cohort shows little impact on clinically significant outcomes

Bajaj J., Kamath P. S., Xie Q., Topazian M., Hayes P., Torre A., et al.
European-Association-for-the-Study-of-the-Liver Congress (EASL), Milan, İtalya, 5 - 08 Haziran 2024, (Özet Bildiri)

26. The impact of tumor budding in patients with hepatocelular carcinoma

Duran o. f., GÖKCAN H., KİREMİTCİ S., YILMAZ V., ÇİFTÇİ A., BODAKÇİ E., et al.
EASL congress 2024, 05 Haziran 2024, (Özet Bildiri)

27. Requrrence of primary sclerosing cholangitis after living donor liver transplantation: experience from turkish registery

ADALI G., harputluoğlu m., AKDOĞAN KAYHAN M., TURAN D., AKARSU M., DANIŞ N., et al.
EASL congress 2024, 05 Haziran 2024, (Özet Bildiri)

28. Histological and clinical disease progression in patients with metabolic associated steatotic liver disease using paired biopsy

ekelik m., TURAN D., GÜMÜŞSOY M., KİREMİTCİ S., BODAKÇİ E., yılmaz V., et al.
EASL congress 2024, 05 Haziran 2024, (Özet Bildiri)

29. KARACİĞER MRG BULGULARI İLE PRİMER HEPATİK AMİLOİDOZ OLGUSU

Can O., Kuru Öz D., Eskalen Z., Duran A., Yamalı S. C., Bodakçı E., et al.
Türk Manyetik Rezonans Derneği 28. Yıllık Bilimsel Toplantısı , Ankara, Türkiye, 16 - 18 Mayıs 2024, ss.216, (Özet Bildiri)

30. HEPATİK EPİTELOİD ANJİOMYOLİPOM OLGUSU: BT VE MRG BULGULARI

Ergüden R. E., Kuru Öz D., Gülpınar B., Kiremitci S., Tüzüner A., Erden G. A., et al.
Türk Manyetik Rezonans Derneği 28. Yıllık Bilimsel Toplantısı , Ankara, Türkiye, 16 - 18 Mayıs 2024, ss.181-182, (Özet Bildiri)

31. DISEASE PROGRESSION IN PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE USING PAIRED LIVER BIOPSY

TURAN GÖKÇE D., Ekelik M. M., Gumussoy M., Kiremitci S., Bodakci E., Yilmaz V., et al.
Digestive Disease Week (DDW), Washington, Kiribati, 18 - 21 Mayıs 2024, cilt.166, (Özet Bildiri)

32. Assessing Hepatic Steatosis by Magnetic Resonance Imaging in Potential Living Liver Donors

Kuru Öz D., Ellik Z., Gürsoy Çoruh A., Gümüşsoy M., Adıgüzel M., Kiremitci S., et al.
AASLD-TASL Hepatology Connect Meeting 2024, İzmir, Türkiye, 16 - 17 Şubat 2024, ss.1-2, (Özet Bildiri)

33. C282Y mutation in hemochromatosis: Single center experience

BODAKÇİ E., GÖKCAN H., GÜMÜŞSOY M., GÜVENİR S. T., YILMAZ V., KARAKAYA M. F., et al.
AASLD-TASL hepatology connect meeting 2024, 16 Şubat 2024, (Özet Bildiri)

34. SAT-519 The impact of tumor budding on tumor biology in patients with hepatocellular carcinoma

DURAN O. F., GÖKCAN H., KİREMİTCİ S., GÜVENİR S. T., YILMAZ V., BODAKÇİ E., et al.
AASLD-TASL hepatology connect meeting, 16 Şubat 2024, (Tam Metin Bildiri)

35. Hepatic steatosis is associated with HbsAg clearnce in patients with chronic hepatitis B infection

BODAKÇİ E., DUMAN S., KİREMİTCİ S., MELEKOĞLU ELLİK Z., GÜMÜŞSOY M., ER R. E., et al.
AASLD-TASL hepatology connect meeting 2024, 16 Şubat 2024, (Özet Bildiri)

36. Assesing Hepatic Steatosis by MRI in potential living liver donors

Kuru Öz d., MELEKOĞLU ELLİK Z., GÜRSOY ÇORUH A., GÜMÜŞSOY M., kırımker o. e., GÖKCAN H., et al.
AASLD-TASL hepatology connect meeting 2024, 16 Şubat 2024, (Özet Bildiri)

37. Histological and Clinical disease Progression in Patients with Metabolic Dysfuntion associated Steatotic Liver Disease Isinig Paired Biopsy

Ekelik M. M., TURAN D., GÜMÜŞSOY M., KİREMİTCİ S., BODAKÇİ E., YILMAZ V., et al.
AASLD-TASL hepatology connect meeting 2024, 16 Şubat 2024, (Özet Bildiri)

38. The impact of tumor budding on tumor biology in patients with hepatocellular carcinoma

Duran O. F., GÖKCAN H., KİREMİTCİ S., GÜVENİR S. T., YILMAZ V., BODAKÇİ E., et al.
AASLD-TASL hepatology connect meeting 2024, 16 Şubat 2024, (Özet Bildiri)

39. Case series of C282Y mutation in the HFE gene in Turkey: Single-center experience

BODAKÇİ E., GÖKCAN H., güvener t., YILMAZ V., ER R. E., KARAKAYA M. F., et al.
19. Euroasian Hepatogastroenterology and Surgery, 13 Kasım 2023, (Tam Metin Bildiri)

40. LIVER FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS DELTA

Bodakçı E., KARAKAYA M. F., KURU ÖZ D., Turan D. G., DUMAN S., MELEKOĞLU ELLİK Z., et al.
aasld 2023, 5 - 08 Kasım 2023, cilt.78, ss.399-400, (Tam Metin Bildiri)

41. Familial NAFLD Cirrhosis Case Series

AKARCA H. T., GÖKCAN H., GÜVENİR S. T., YILMAZ V., İDİLMAN R.
19. Euroasian Hepatogastroenterology and Surgery, 13 Kasım 2023, (Tam Metin Bildiri)

42. noninvazive fibrosis markers for assesment for liver fibrosis in patients with chronic hepatitis delta

KARAKAYA M. F., KURU ÖZ D., Turan Gökçe D., DUMAN S., Ellik Z. M., GÜMÜŞSOY M., et al.
AASLD 2023 congress, 10 Kasım 2023, (Tam Metin Bildiri)

43. Noninvazive fibrosis markers for assesment for liver fibrosis in patients with chronic hepatitis delta

KARAKAYA M. F., KURU ÖZ D., Turan D., DUMAN S., MELEKOĞLU ELLİK Z., GÜMÜŞSOY M., et al.
AASLD 2023 congress, Amerika Birleşik Devletleri, 10 Kasım 2023, (Özet Bildiri)

44. GLOBAL PREVALENCE OF INFECTIONS AND IMPACT OF REGIONAL VARIATIONS ON OUTCOMES: MULTI-NATIONAL CONSORTIUM OF CIRRHOSIS STUDY

Xie Q., Cao Z., Choudhury A. K., Kamath P. S., Topazian M., Hayes P. C., et al.
Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, Amerika Birleşik Devletleri, 10 - 14 Kasım 2023, (Özet Bildiri)

45. PRIVATE INSURANCE ACCESS IS ASSOCIATED WITH HIGHER LIVER TRANSPLANT LISTING AND TRANSPLANT ACCESS AND LOWER MORTALITY COMPARED TO NATIONAL INSURANCES IN A LARGE MULTINATIONAL COHORT OF INPATIENTS WITH CIRRHOSIS

Bajaj J. S., Wong F., Xie Q., Kamath P. S., Topazian M., Hayes P. C., et al.
Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, Amerika Birleşik Devletleri, 10 - 14 Kasım 2023, (Özet Bildiri)

46. A STUDY OF ACUTE LIVER INJURY ASSOCIATED WITH ORNIDAZOLE: ANALYSIS OF 82 CASES IN TURKIYE

TURAN İ., DURMAZER E. N., Vatansever S., Caliskan A. R., Harputluoglu M., Efe C., et al.
Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, Amerika Birleşik Devletleri, 10 - 14 Kasım 2023, (Özet Bildiri)

47. NON - INVASIVE FIBROSIS MARKERS FOR ASSESMENT OF LIVER FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS DELTA

BODAKÇİ E., KARAKAYA M. F., KURU ÖZ D., Gokce D., DUMAN S., Ellik Z., et al.
Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, Amerika Birleşik Devletleri, 10 - 14 Kasım 2023, cilt.78, (Özet Bildiri)

48. REGIONAL DIFFERENCES IN ACUTE KIDNEY INJURY PREVALENCE, CLINICAL CHARACTERISTICS AND PATIENT OUTCOMES IN A MULTI-NATIONAL CONSORTIUM OF INPATIENTS WITH CIRRHOSIS

Wong F., George J., Hayes P. C., Torre A., Kamath P. S., Xie Q., et al.
Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, Amerika Birleşik Devletleri, 10 - 14 Kasım 2023, (Özet Bildiri)

49. ALCOHOL-RELATED ETIOLOGY IS AN INDEPENDENT PREDICTOR OF INPATIENT MORTALITY IN PATIENTS WITH CIRRHOSIS IN A PROSPECTIVE GLOBAL CONSORTIUM

Choudhury A. K., Wong F., Xie Q., Kamath P. S., Topazian M., Hayes P. C., et al.
Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, Amerika Birleşik Devletleri, 10 - 14 Kasım 2023, (Özet Bildiri)

50. The role of PAGE-B score in predicting the devolepment of hepatocelular cancer in patients with chronic delta hepatitis

KESKİN O., KALKAN Ç., GÜMÜŞSOY M., TUNÇ E., BOZDAYI A. M., ZEYBEL M., et al.
EASL Congress, Vienna, Avusturya, 21 - 24 Haziran 2023, cilt.78, ss.1109-1110, (Özet Bildiri)

51. development of Metabolic Disorders in Transplant Recepients

Erdemir G., GÖKCAN H., Gürsoy Çoruh A., GÜLPINAR B., MELEKOĞLU ELLİK Z., GÜMÜŞSOY M., et al.
EASL Congress 21-24 June 2023, Avusturya, 21 - 24 Haziran 2023, cilt.78, ss.477-478, (Tam Metin Bildiri)

52. development of Metabolik disorders in Liver transplant recepients

Erdemir G., GÖKCAN H., İDİLMAN R.
The 2023 International congress of ILTS ELITA and LICAGE, 03 Mayıs 2023, (Tam Metin Bildiri)

53. A combination of non-invasive tests for the detection of significant fibrosis in patients with metabolic dysfunction-associated steatotic liver disease is not superior to magnetic resonance elastography alone.

DUMAN S., KURU ÖZ D., GÜMÜŞSOY M., KİREMİTCİ S., GÖKCAN H., ÖZERCAN A. M., et al.
AASLD-TASL hepatology connect meeting, 28 - 29 Nisan 2023, (Tam Metin Bildiri)

54. Development of Metabolic Disorders in Transplant Recepients

erdemir g., GÖKCAN H., GÜRSOY ÇORUH A., GÜMÜŞSOY M., DUMAN S., İDİLMAN R.
AASLD-TASL hepatology connect meeting, 28 - 29 Nisan 2023, (Tam Metin Bildiri)

55. effect of prognostic tests on disease outcome of alcohol-related liver disease

zengin b. a., GÜMÜŞSOY M., DUMAN S., BODAKÇİ E., ÖZERCAN A. M., ER R. E., et al.
AASLD-TASL hepatology connect meeting, 28 Nisan 2023, (Tam Metin Bildiri)

56. Natural Disease outcome in patients with NAFLDÇ a study with paired liver biopsies

GÜMÜŞSOY M., TURAN D., ekelik m., KİREMİTCİ S., DUMAN S., GÜVENİR S. T., et al.
AASLD-TASL hepatology connect meeting, 28 Nisan 2023, (Tam Metin Bildiri)

57. A case of AFP producing cholangiocarcinoma

BODAKÇİ E., GÜMÜŞSOY M., GÜVENİR S. T., KARAKAYA F., GÖKCAN H., İDİLMAN R.
AASLD-TASL hepatology connect meeting, 28 - 29 Nisan 2023, (Tam Metin Bildiri)

58. İdentification of risk factors for alcohol relapse in liver transplant patients with alcohol- related liver disease.

TURAN D., GÜNŞAR F., harputluoğlu m., KABAÇAM G., GÖKCAN H., AKARSU M., et al.
EASL Congress 21-24 June 2023, 21 Nisan 2023, (Tam Metin Bildiri)

59. A Combination Of Non-Invasive Tests In Detection Of NAFLD-Related Advanced Fibrosis Is Not Superior To MRE Alone

Duman S., Gümüşsoy M., Kuru D., Kiremitci S., Gökcan H., Bodakçı E., et al.
39. Jahrestagung der Deutschen Arbeitsgemeinschaft zum Studium der Leber, Bochum, Almanya, 27 - 28 Ocak 2023, cilt.61, ss.30, (Özet Bildiri)

60. MEFIB AND MAST SCORES ASSESSMENT OF INCIDENT LIVER-RELATED OUTCOMES IN NONALCOHOLIC FATTY LIVER DISEASE: AN INDIVIDUAL PATIENT META-ANALYSIS

Noureddin N., Ajmera V., Bergstrom J., Huang D., Siddiqi H., Majzoub A. M., et al.
American Association for the Study of Liver Diseases, The Liver Meeting (AASLD 2022), Amerika Birleşik Devletleri, 4 - 08 Kasım 2022, (Özet Bildiri)

61. Alkol Dışı Yağlı Karaciğer Hastalığı Doğal Seyri: Ardışık İkili Karaciğer Biyopsilerinin Karşılaştırılması

GÜMÜŞSOY M., TURAN D., EKELİK M., KİREMİTCİ S., BODAKÇİ E., DUMAN S., et al.
39. ULUSAL GASTROENTEROLOJİ HAFTASI, Antalya, Türkiye, 22 Kasım 2022, (Özet Bildiri)

62. Alkole Bağlı Karaciğer Hastalığında Prognostik Non-İnvasif Testlerin Hastalık Sonucunu Öngörmede Etkinliği

ZENGİN B. A., GÜMÜŞSOY M., DUMAN S., BODAKÇİ E., GÜVENİR S. T., MELEKOĞLU ELLİK Z., et al.
39. ULUSAL GASTROENTEROLOJİ HAFTASI, Antalya, Türkiye, 22 Kasım 2022, (Özet Bildiri)

63. Effect of prognostic noninvasive tests on disease outcome of alcohol related liver disease

zengin a., GÜMÜŞSOY M., DUMAN S., BODAKÇİ E., GÜVENİR S. T., MELEKOĞLU ELLİK Z., et al.
aasld 2022, 04 Kasım 2022, (Özet Bildiri)

64. Natural disease Outcome in patients with NAFLD: A study with paired liver biopsy

GÜMÜŞSOY M., Turan Gökçe D., KİREMİTCİ S., BODAKÇİ E., DUMAN S., MELEKOĞLU ELLİK Z., et al.
aasld 2022, 04 Kasım 2022, (Özet Bildiri)

65. FUNCTIONAL CURE WİTH LANOFARNİB-BASED THERAPY IN CHRONİC HEPATİTİS DELTA

YURTAYDIN S. C., TUNÇ E., GÜMÜŞSOY M., KESKİN O., GENÇDAL G., ZEYBEL M., et al.
AASLD-TASL CONNECT REGIONAL MEETING, 01 Ocak 2022, cilt.76, ss.297-298, (Özet Bildiri)

66. Metabolic Syndrome in liver Transplant recipient

KARA G., GÖKCAN H., İDİLMAN R.
AASLD 2022, 4 - 08 Kasım 2022, (Özet Bildiri)

67. Preliminary Results of The effectiveness and safety of Tenofovir alafenamide Fumarate Prophylaxis in HBV individuals, who received Chemo/Immunsupression therapy

GÜNDÜZ F. F., DURAK S., ÜNSAL Y., DEMİR M., MELEKOĞLU ELLİK Z., YILDIRIM A. E., et al.
ınternational Liver congress ILC 2022 (EASL), 22 Haziran 2022, (Özet Bildiri)

68. Effectiveness of MRI methods in the asssement of hepatic steatosis in living liver donors

KURU ÖZ D., MELEKOĞLU ELLİK Z., GÜRSOY ÇORUH A., GÜMÜŞSOY M., DUMANLI S., ER R. E., et al.
ınternational Liver congress ILC 2022 (EASL), 22 Haziran 2022, (Özet Bildiri)

69. Trends and causes of etiology in adult liver transplant patients: multicenter study

AKARSU M., Harputluoğlu M., YILMAZ S., GENÇDAL G., AKYILDIZ M., DİNÇER D., et al.
ınternational Liver congress ILC 2022 (EASL), 22 - 26 Haziran 2022, (Özet Bildiri)

70. Real Life Efficacy and tolerability of Tenofovir alafenamide fumarate in patients with hepatitis B virus related cirrhosis

YAPALI S., GÖKCAN H., DURAK S., MELEKOĞLU ELLİK Z., ADANIR H., GÜNDÜZ F. F., et al.
ınternational Liver congress ILC 2022 (EASL), 22 - 26 Haziran 2022, (Özet Bildiri)

71. Real life efficacy and tolerability of Tenofovir alafenamide fumarate in liver transplant recipients: a multicenter study (SAT416)

GÖKCAN H., YAPALI S., HARPUTLUOĞLU M. M. M., MELEKOĞLU ELLİK Z., GÖKÇEN P., ADANIR H., et al.
EASL The International Liver Congress, London, Kanada, 26 Haziran 2022, (Özet Bildiri)

72. Real life efficacy and tolerability of Tenofovir Alafenamide Fumarate in patients with hepatitis-B virus-related cirrhosis (SAT421)

YAPALI S., GÖKCAN H., DURAK S., MELEKOĞLU ELLİK Z., GÜZELBULUT F., VATANSEVER S., et al.
EASL The International Liver Congress, London, Kanada, 22 Haziran 2022, (Özet Bildiri)

73. Real Life Efficacy and tolerability of Tenofovir alafenamide fumarate in liver transplant recipients: A multicenter study

YAPALI S., GÖKCAN H., MELEKOĞLU ELLİK Z., GÖKÇEN P., ADANIR H., DURAK S., et al.
ILTS 2022, 04 Mayıs 2022, (Özet Bildiri)

74. Real life efficacy and tolerability of tenofovir alafenamde fumarate in liver transplant recipients: A multicenter study

YAPALI S., GÖKCAN H., harputluoğlu M., MELEKOĞLU ELLİK Z., GÖKÇEN P., ADANIR H., et al.
AASLD TASL Digital Hepatology Meeting, Türkiye, 14 - 15 Ocak 2022, cilt.3, ss.4, (Tam Metin Bildiri)

75. Biliary complications and management in liver transplant recipients with duct to duct anastomosis: A single center experience

KARAKAYA M. F., ÇINAR K., ER R. E., KIRIMKER E. O., BALCI D., ÖZERCAN A. M., et al.
AASLD-TASL Digital Hepatology Meeting, 14 Ocak 2022, (Özet Bildiri)

76. Presentation and outcome of autoimmune hepatitis during pregnancy

örmeci a., DUMAN S., İSTEMİHAN Z., GÖKCAN H., ÇAVUŞ B., ARSLAN K., et al.
AASLD-TASL digital Hepatology Connect, 14 Ocak 2022, (Özet Bildiri)

77. Trends and changes of etiology in adult liver transplant patients: mulitcenter study

AKARSU M., Harputluoğlu M., YILMAZ S., AKYILDIZ M., GENÇDAL G., polat k. y., et al.
AASLD-TASL digital Hepatology Connect, 14 Ocak 2022, (Tam Metin Bildiri)

78. Bliary Complications and Management in Liver Transplant Patients with Duct to Duct Anastomotis: Single Center Experience

KARAKAYA M. F., ÇINAR K., ER R. E., KIRIMKER E. O., BALCI D., ÖZERCAN A. M., et al.
AASLD-TASL digital Hepatology Connect, 14 Ocak 2022, (Özet Bildiri)

79. The Effect of Clinicopathologic findings of Hepatosellüler carcinoma on posttransplant survival: A multicenter kohort from TASL Liver Transplantation special İnterest group

AKYILDIZ M., GENÇDAL G., İNCE V., Harputluoğlu M., ZEYTÜNLÜ M., KILIÇ M., et al.
AASLD-TASL digital Hepatology Connect, 14 - 16 Ocak 2022, (Tam Metin Bildiri)

80. Real Life Efficacy and tolerability of Tenofovir alafenamide fumarate in patiernts with hepatitis B virus related cirrhosis

YAPALI S., GÖKCAN H., DURAK S., MELEKOĞLU ELLİK Z., VATANSEVER S., ADANIR H., et al.
AASLD-TASL digital Hepatology Connect, 14 Nisan 2022, (Özet Bildiri)

81. Efficacy and Safety of Tenofovir alafenamide in hepatitis B virus infected patients with chronic hemodialsis and renal transplantation: a preliminary result

ADANIR H., ÖZER ETİK D., YILDIRIM A. E., YAPALI S., ARI D., GÖKCAN H., et al.
AASLD-TASL digital Hepatology Connect, 14 Ocak 2022, (Özet Bildiri)

82. Development of Metabolic Disorders İn Liver Transplant Patients

KARA G., GÖKCAN H., GÜMÜŞSOY M., DUMAN S., İDİLMAN R.
AASLD-TASL digital Hepatology Connect, 14 Ocak 2022, (Özet Bildiri)

83. Kemoterapi ve İmmünosüpresif Tedavi Alan Hastalarda Hepatit B Reaktivasyon Profilaksisinde Tenofovir Alafenamid Fumaratın Etkinliği ve Güvenliği: Çok Merkezli-Gözlemsel Çalışmanın ilk Sonuçları

GÜNDÜZ F., DURAK S., ÜNSAL Y., DEMİR M., MELEKOĞLU ELLİK Z., YILDIRIM E., et al.
38. Ulusal Gastroenteroloji Haftası 16-21 Kasım 2021, Antalya, 16 Kasım 2021, (Özet Bildiri)

84. ’Duct to Duct Anastomozlu’ Karaciğer Transplantasyon Hastalarında Biliyer Komplikasyonlar ve Yönetimi: Tek Merkez Deneyimi

KARAKAYA M. F., ÇINAR K., ER R. E., KIRIMKER E. O., BALCI D., ÖZERCAN A. M., et al.
38. ULUSAL GASTROENTEROLOJİ HAFTASI, Antalya, Türkiye, 16 Kasım 2021, (Özet Bildiri)

85. Real life Efficay and Tolerability of Tenofovir alafanamide fumarate in patients with hepatitis B virus related cirrhosis and liver transplant recepients: a prilimanary result

YAPALI S., GÖKCAN H., Harputluoğlu M., MELEKOĞLU ELLİK Z., AKARSU M., ADANIR H., et al.
AASLD 2021 congress, 05 Kasım 2021, (Özet Bildiri)

86. Karaciğer Donörlerinin Preoperatif Yağlanma Değerlendirilmesinde MRG Yöntemlerinin Etkinliği

Kuru Öz D., Melekoğlu Ellik Z., Gürsoy Çoruh A., Adıgüzel M., Gümüşsoy M., Duman S., et al.
38. Ulusal Gastroenteroloji Haftası, 2021, Antalya, Türkiye, 16 Ekim - 21 Kasım 2021, ss.160-161, (Özet Bildiri)

87. Real Life Efficacy and Tolerability of Tenofovir Alafenamide Fumarate in Patients with Hepatitis B Virus-related Cirrhosis and Liver Transplant Recipients. A-Preliminary Result (798)

YAPALI S., GÖKCAN H., HARPUTLUOĞLU M. M. M., MELEKOĞLU ELLİK Z., AKARSU M., DURAK S., et al.
AASLD the Liver Meeting Digital Experience, Amerika Birleşik Devletleri, 12 Kasım 2021, cilt.74, ss.490, (Özet Bildiri)

88. Efficacy and Safety of TAF in Hepatitis B virus infected patiebts with chronic hemodialiss and renal transplantation: A prelimanry result

ADANIR H., etik d. ö., YILDIRIM A. E., YAPALI S., COŞAR A. M., ARI D., et al.
AASLD 2021 congress, 06 Kasım 2021, (Özet Bildiri)

89. association. between non-alcoholic fatty liver disease and extrahepatic malignancy

GÜMÜŞSOY M., İDİLMAN R., GÖKCAN H., BODAKÇİ E., özercan m., ER R. E., et al.
EASL gongress 2021, 23 Haziran 2021, (Özet Bildiri)

90. Outcome of COVID-19 in Patients with Autoimmune Hepatitis: An International Multi-Centre Study

EFE C., BATIBAY E., DHANASEKARAN R., LAMMERT C., ALOMAN C., MASSOUMİ H., et al.
17. Ulusal Hepato-Gastroenteroloji Kongresi & Middle East & North Africa EUS Club 4th MENA EUS & ERCP Workshop, 17 - 19 Haziran 2021, (Özet Bildiri)

91. Kemoterapi ve İmmünsüpresif Tedavi Alan Hastalarda Hepatit B Reaktivasyon Profilaksisinde Tenofovir Alafenamide Fumarat’ın Etkinliği ve Güvenirliği: Çok Merkezli-Gözlemsel Çalışmanın İlk Sonuçları

GÜNDÜZ F., ÜNSAL Y., MELEKOĞLU ELLİK Z., MEHDİYEV S., YILDIRIM E., ADANIR H., et al.
13. ULUSAL HEPATOLOJİ KONGRESİ ULUSLARARASI KATILIMLI, 28 - 30 Mayıs 2021, (Özet Bildiri)

92. EFFICACY AND SAFETY OF TENOFOVIR ALAFENAMIDE IN CHRONIC HEPATITIS B PATIENTS WITH CHRONIC HEMODIALYSIS AND KIDNEY TRANSPLANTATION‐ REALITY STUDY

ADANIR H., MELEKOĞLU ELLİK Z., YILDIRIM A. E., GÜNDÜZ F. F., GÖKCAN H., YARAŞ S., et al.
AASLD‐TASL Digital Hepatology Connect Meeting, 2021, 15 Eylül 2021, (Özet Bildiri)

93. Non-alcoholic fatty liver disease and extrahepatic malignancy

Gümüşsoy M., Turan Gökçe D., Ulaş B. B., Koç Ö., Karataş G., Bodakçı E., et al.
AASLD-TASL digital Hepatology Connect, 15 Ocak 2021, (Tam Metin Bildiri)

94. The analysis of liver transplant patients with COVİD-19 infection: a national cohort

KABAÇAM G., TURAN İ., KIYICI M., MELEKOĞLU ELLİK Z., dolu S., Dayangaç M., et al.
AASLD-TASL digital Hepatology Connect, İstanbul, Türkiye, 15 - 16 Ocak 2021, cilt.2, ss.24-25, (Özet Bildiri)

95. MAGNETIC RESONANCE ELASTOGRAPHY AND TRANSIENT ELASTOGRAPGHY TO ASSESS HEPATIC STETAOSIS AND LIVER FIBROSIS IN THE LIVER TRANSPLANT SETTING

Ellik Z., İDİLMAN İ. S., Kartal A. C., Balaban Y. H., KARÇAALTINCABA M., İDİLMAN R.
Liver Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), ELECTR NETWORK, 13 - 16 Kasım 2020, cilt.72, (Özet Bildiri)

96. AMAP RISK SCORE PREDICTS HEPATOCELLULAR CARCINOMA DEVELOPMENT IN CHRONIC HEPATITIS PATIENTS: AN INTERNATIONAL COHORT COLLABORATION

Fan R., Papatheodoridis G., Sun J., Innes H., Toyoda H., Xie Q., et al.
Liver Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), ELECTR NETWORK, 13 - 16 Kasım 2020, cilt.72, (Özet Bildiri) Sürdürülebilir Kalkınma

97. Diagnostic accuracy of liver stiffness measurement by fibroscan in liver transplant recipients

MELEKOĞLU ELLİK Z., ÇALIŞKAN A., DUMAN S., GÜMÜŞSOY M., ÖZERCAN A. M., ER R. E., et al.
EASL: The Digital International Liver Congress, 27 - 29 Ağustos 2020, cilt.73, ss.528, (Özet Bildiri)

98. Outcomes following deceased and live donor livertransplantation for the indication of acute liver failure: amulticenter experience

TURAN İ., ALADAĞ M., HARPUTLUOĞLU M. M. M., YILMAZ S., GENÇDAL G., POLAT K. Y., et al.
The Digital International Liver Congress (EASL) 2020, 27 - 29 Ağustos 2020, cilt.73, ss.227, (Tam Metin Bildiri)

99. ASSOCIATION BETWEEN NON-ALCOHOLOIC FATTY LIVER DISEASE AND SUBCLINICAL ATHEROSCLEROSIS AND MYOCARDIAL DYSFUNCTION USING MULTIMODALITY IMAGING

ULAŞ B. B., ÖZYÜNCÜ N., ÇALIŞKAN KARTAL A., PEKER E., TURAN GÖKÇE D., GÜMÜŞSOY M., et al.
ANNUAL MEETING OF AASLD / LIVER MEETING, 8 - 12 Kasım 2019, (Tam Metin Bildiri)

100. ASSOCIATION BETWEEN NON-ALCOHOLIC FATTY LIVER DISEASE AND SUBCLINICAL ATHEROSCLEROSIS AND MYOCARDIAL DYSFUNCTION USING MULTIMODALITY IMAGING

Ulas B. B., ÖZYÜNCÜ N., Kartal A. C., PEKER E., Gokce D., Gumussoy M., et al.
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Massachusetts, Amerika Birleşik Devletleri, 8 - 12 Kasım 2019, cilt.70, (Özet Bildiri)

101. NATURAL HISTORY OF INACTIVE HBsAg CARRIERS: A 10-YEAR PROSPECTIVE FOLLOW-UP STUDY

Yurdaydin C., Keskin O., Yurdcu E., Yakut M., Seven G., Kabacam G., et al.
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Massachusetts, Amerika Birleşik Devletleri, 8 - 12 Kasım 2019, cilt.70, (Özet Bildiri)

102. SIMILAR RISK OF HEPATOCELLULAR CARCINOMA (HCC) DEVELOPMENT DURING LONG-TERM ENTECAVIR (ETV) OR TENOFOVIR DISOPROXIL FUMARATE (TDF) THERAPY IN CAUCASIAN CHRONIC HEPATITIS B (CHB) PATIENTS

Papatheodoridis G. V., Dalekos G. N., Yurdaydin C., Sypsa V., van Boemmel F., Buti M., et al.
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Massachusetts, Amerika Birleşik Devletleri, 8 - 12 Kasım 2019, cilt.70, (Özet Bildiri) Sürdürülebilir Kalkınma

103. TREATMENT DISCONTINUATION IN HBEAG-NEGATIVE CHRONIC HEPATIT B IS A VIABLE OPTION IN NON-CIRRHOTIC GENOTYPE D CHRONIC HEPATITIS B PATIENTS

ŞAH ÜNAL F. T., Keskin O., Yurdcu E., Yilmaz Y., KARAKAYA M. F., Kartal A., et al.
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Massachusetts, Amerika Birleşik Devletleri, 8 - 12 Kasım 2019, cilt.70, (Özet Bildiri) Sürdürülebilir Kalkınma

104. TÜRKİYE’DE HEPATİT C ELİMİNASYONU YOL HARİTASI ÖNERİLERİ VE ÇALIŞTAY RAPORU

AKARCA U. S., AYGEN B., bodur h., GÜNER H. R., İDİLMAN R., KAYMAKOĞLU S., et al.
XI.Ulusal Viral Hepatit Simpozyumu, Türkiye, 14 - 16 Haziran 2019, (Özet Bildiri) Sürdürülebilir Kalkınma

105. ETIOLOGY OF CIRRHOSIS CHANGING TRENDS OVER THE YEARS: A SINGLE-CENTER TURKISH EXPERIENCE

İDİLMAN R., ÇALIŞKAN KARTAL A., AYDOĞAN M., KARAKAYA M. F., KALKAN Ç., ÖNEM S., et al.
DDW 2019, 19 - 21 Mayıs 2019, (Özet Bildiri)

106. E ANTİJEN NEGATİF KRONİK HEPATİT B HASTALARINDA POTENT ANTİVİRAL TEDAVİLERİN KESİLMESİ SONRASI TAKİP SONUÇLARI VE RELAPS ORANLARI

KESKİN O., KARAKAYA M. F., MELEKOĞLU ELLİK Z., TUNÇ E., BOZDAYI A. M., İDİLMAN R., et al.
12. ULUSAL HEPATOLOJİ KONGRESİ, Antalya, Türkiye, 1 - 05 Mayıs 2019, (Özet Bildiri)

107. 10 YILLIK PROSPEKTİF ÇALIŞMADA DÜŞÜK VİRAL YÜKLÜ HBV TAŞIYICILARI REAKTİVASYONDAN ZİYADE HBSAG KAYBETMEYE YATKINDIR.

KESKİN O., YAKUT M., YURDCU E., KALKAN Ç., AGAYEVA S., YILMAZ Y., et al.
12. ULUSAL HEPATOLOJİİ KONGRESİ, Antalya, Türkiye, 1 - 05 Mayıs 2019, (Özet Bildiri)

108. FREQUENCY, SEVERİTY AND İMPACT OF PEG-IFNA-ASSOCİATED FLARES İN HDV İNFECTİON: RESULTS FROM THE HIDIT-II STUDY

TUNÇ E., KESKİN O., İDİLMAN R., BOZDAYI A. M., YURTAYDIN S. C.
54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Vienna, Avusturya, 10 - 14 Nisan 2019, cilt.70, ss.466, (Özet Bildiri)

109. Prediction of elastographic reversion of cirrhosis after 5 years of entecavir or tenofovir disoproxil fumarate therapy in caucasian chronic hepatitis B patients

Papatheodoridis G., Dalekos G., Yurdaydin C., Sypsa V., van Bommel F., Buti M., et al.
International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Vienna, Avusturya, 10 - 14 Nisan 2019, cilt.70, (Özet Bildiri) Sürdürülebilir Kalkınma

110. Plasma metabolomic changes modulate the impact of Middle Eastern versus Western Diet in an international cirrhosis cohort

Cox I. J., İDİLMAN R., Fagan A., Turan D., Ajayi L., Karakaya F., et al.
International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Vienna, Avusturya, 10 - 14 Nisan 2019, cilt.70, (Özet Bildiri)

111. Frequency, severity and impact of Peg-IFNa-associated flares in HDV infection: Results from the HIDIT-II study

Hardtke S., Wedemeyer H., Caruntu F. A., Curescu M., Kendal Y., AKARCA U. S., et al.
International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Vienna, Avusturya, 10 - 14 Nisan 2019, cilt.70, (Özet Bildiri)

112. KRONİK HEPATİT B'DE POTENT ANTİVİRAL TEDAVİNİN KESİLMESİ SONRASI TAKİP SONUÇLARI VE RELAPS ORANI

KESKİN O., KARAKAYA M. F., MELEKOĞLU ELLİK Z., TUNÇ E., BOZDAYI A. M., İDİLMAN R., et al.
35. ULUSAL GASTROENTEROLOJİ HAFTASI, Antalya, Türkiye, 21 - 25 Kasım 2018, (Özet Bildiri)

113. DÜŞÜK VİRAL YÜKLÜ HBV TAŞIYICILARINDA DOĞAL SEYİR:10 YILLIK PROSPEKTİF TAKİP SONUÇLARI

KESKİN O., TUNÇ E., KALKAN Ç., BOZDAYI A. M., İDİLMAN R., YURTAYDIN S. C.
35. ULUSAL GASTROENTEROLOJİ HAFTASI, Antalya, Türkiye, 21 - 25 Kasım 2018, (Özet Bildiri)

114. DELTA HEPATİTTE TEDAVİ YANITINI ÖNGÖRMEDE NONİNVAZİV FİBROZİS SKORLARI FAYDALI DEĞİLDİR

KESKİN O., TUNÇ E., KALKAN Ç., MELEKOĞLU ELLİK Z., BOZDAYI A. M., İDİLMAN R., et al.
35. ULUSAL GASTROENTEROLOJİ HAFTASI, Antalya, Türkiye, 21 - 25 Kasım 2018, (Özet Bildiri)

115. KRONİK HEPATİT DELTADA KARACİĞER BİYOPSİSİ TEDAVİ ETKİNLİĞİNİ DEĞERLENDİRMEDE OPTİMAL BİR SEÇENEK DEĞİLDİR

MELEKOĞLU ELLİK Z., İDİLMAN R., TUNÇ E., BOZDAYI A. M., KESKİN O., YURTAYDIN S. C.
35. ULUSAL GASTROENTEROLOJİ HAFTASI, Antalya, Türkiye, 21 - 25 Kasım 2018, (Özet Bildiri)

116. COMPARİSON OF THE EFFİCACY OF SHORT TERM AND LONG TERM NUCLEOS(T)İDE ANALOG TREATMENT İN CHRONİC DELTA HEPATİTİS

YURTAYDIN S. C., KESKİN O., KARAKAYA M. F., MELEKOĞLU ELLİK Z., TUNÇ E., BOZDAYI A. M., et al.
35. ULUSAL GASTROENTEROLOJİ HAFTASI, Antalya, Türkiye, 21 Kasım 2018, (Özet Bildiri)

117. Comparison of the efficacy of short term and long term nucleos(t)ide analog treatment in chronic delta hepatitis

YURTAYDIN S. C., KESKİN O., KARAKAYA M. F., YILMAZ Y., ÇALIŞKAN KARTAL A., MELEKOĞLU ELLİK Z., et al.
35. ULUSAL GASTROENTEROLOJİ HAFTASI, Antalya, Türkiye, 21 Kasım 2018, (Özet Bildiri)

118. Nonnvasve Fbross Scores Are Not Useful for Predcton of Response to Treatment n Chronc Delta Hepatts

KESKİN O., YURDCU E., KALKAN Ç., ÇALIŞKAN KARTAL A., ELLİK Z., BOZDAYI A. M., et al.
AASLD LIVER MEETING 2018, San-Francisco, Kostarika, 9 - 13 Kasım 2018, (Özet Bildiri)

119. Predicition and need for surveillance of hepatocellular carcinoma (HCC) development after the first 5 years of entecavir or tenofovir disoproxil fumarate therapı in Caucasian chronic hepatitis B patients of the PAGE-B Cohort.

Papatheodoridis G., Dalekos G., YURTAYDIN S. C., Sypsa V., Bommel V., Buti m., et al.
AASLD, 9 - 13 Kasım 2018, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

120. Prediction and Need for Surveillance of Hepatocellular Carcinoma (HCC) Development after the First 5 Years of Entecavir (ETV) or Tenofovir Disoproxil Fumarate (TDF) Therapy in Caucasian Chronic Hepatitis B (CHB) Patients of the PAGE-B Cohort

Papatheodoridis G. V., Dalekos G. N., Yurdaydin C., Sypsa V., van Bommel F., Buti M., et al.
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, San-Francisco, Kostarika, 9 - 13 Kasım 2018, cilt.68, (Özet Bildiri) Sürdürülebilir Kalkınma

121. Noninvasive Fibrosis Scores Are Not Useful for Prediction of Response to Treatment in Chronic Delta Hepatitis

Keskin O., Yurdcu E., Kalkan C., Kartal A., Ellik Z., Bozdayi M., et al.
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, San-Francisco, Kostarika, 9 - 13 Kasım 2018, cilt.68, (Özet Bildiri) Sürdürülebilir Kalkınma

122. ALT Levels and Risk of Hepatocellular Carcinoma (HCC) in Caucasian Chronic Hepatitis B (CHB) Patients Under Long-Term Therapy with Entecavir (ETV) or Tenofovir Disoproxil Fumarate (TDF)

Papatheodoridis G. V., Dalekos G. N., Yurdaydin C., Sypsa V., van Bommel F., Buti M., et al.
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, San-Francisco, Kostarika, 9 - 13 Kasım 2018, cilt.68, (Özet Bildiri) Sürdürülebilir Kalkınma

123. Patient Selection and Preparation for Liver Transplantation

İDİLMAN R.
APASL Single Topic Non-Responders, 27 - 29 Eylül 2018, (Tam Metin Bildiri)

124. Real world data on safety and efficacy of Ledipasvir Sofosbuvir ± RBV, Ombitasvir / Paritaprevir / Ritonavir ± Dasabuvir ± RBV combination therapy for chronic hepatitis C. A Turkey experience.

DEMİR M., DANIŞ N., KANİ H. T., YILDIRIM A. E., BALKAN A., DEĞERTEKİN M. B., et al.
APASL Single Topic Conference, İstanbul, Türkiye, 27 - 29 Eylül 2018, (Özet Bildiri) Sürdürülebilir Kalkınma

125. A PHASE 2 DOSE-OPTİMİZATİON STUDY OF LONAFARNİB WİTH RİTONAVİR FOR THE TREATMENT OF CHRONİC DELTA HEPATİTİS-ANALYSİS FROM THE LOWR HDV-2 STUDY USİNG THE ROBOGENE (R) REAL-TİME qPCR HDV RNA ASSAY

YURTAYDIN S. C., İDİLMAN R., KESKİN O., KALKAN Ç., KARAKAYA M. F., TUNÇ E., et al.
16th International Symposium on Viral Hepatitis and Liver Diseases (ISVHLD), Toronto, Kanada, 14 - 17 Haziran 2018, cilt.24, ss.10, (Özet Bildiri)

126. Türkiye’deki Hepatit C Virüs 1a ve 1b Genotiplerinde NS3, NS5A ve NS5B Bölgelerindeki Anti-Viral Direnç Varyantları

TUNÇ E., KARATAYLI E., GÖKAHMETOĞLU S., ÖZEN KARATAYLI S. C., İDİLMAN R., YURTAYDIN S. C., et al.
2. ULUSAL VİROLOJİ GÜNLERİ, İzmir, Türkiye, 22 - 24 Mart 2018, (Özet Bildiri)

127. HEPATİT C ENFEKSİYONUNA BAĞLI DEKOMPANZE SİROZ HASTALARINDA VE KRONİK HEPATİT C ENFEKSİYONU NEDENİYLE KARACİĞER NAKLİ OLANLARDA LEDİPASVİR/SOFOSBUVİR TEDAVİSİNİN ETKİLİLİĞİ: TÜRKİYE ERKEN ERİŞİM PROGRAMI SONUÇLARI

İDİLMAN R., DEMİR M., ALADAĞ M., KAYMAKOĞLU S., EROL C., ÇAVUŞ B., et al.
34. ULUSAL GASTROENTEROLOJİ HAFTASI, Türkiye, 1 - 06 Aralık 2017 Sürdürülebilir Kalkınma

128. OTOIMMÜN KARACIĞER HASTALIKLARINA EŞLIK EDENEKSTRAHEPATIK OTOIMMÜN HASTALIKLAR VE HASTALIK SEYRI ÜZERINE ETKISI

KARAKAYA M. F., ÖZTEKİN Ş., ÖZTÜRK UÇAR Y., KALKAN Ç., ELHAN A. H., SOYKAN A. İ., et al.
UGH 2017, Türkiye, 1 - 06 Aralık 2017, (Özet Bildiri)

129. Türkiye’deki Farklı HCV Genotiplerinde NS3, NS5A ve NS5B Bölgelerindeki Anti-Viral Direnç Varyantları

TUNÇ E., KARATAYLI E., GÖKAHMETOĞLU S., ÖZEN KARATAYLI S. C., İDİLMAN R., YURTAYDIN S. C., et al.
4. ULUSAL KLİNİK MİKROBİYOLOJİ KONGRESİ, Antalya, Türkiye, 8 - 12 Kasım 2017, (Özet Bildiri)

130. THE PRENYLATİON İNHİBİTOR LONAFARNİB CAN İNDUCE POST-TREATMENT VİRAL CLEARANCE İN PATİENTS WİTH CHRONİC DELTA HEPATİTİS RESULTİNG İN ALT NORMALİZATİON AND REGRESSİON OF FİBROSİS

YURTAYDIN S. C., İDİLMAN R., KALKAN Ç., KARAKAYA M. F., KESKİN O., TUNÇ E., et al.
52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Amsterdam, Hollanda, 19 - 23 Nisan 2017, cilt.66, ss.259, (Özet Bildiri)

131. A PHASE 2 DOSE-OPTİMİZATİON STUDY OF LONAFARNİB WİTH RİTONAVİR FOR THE TREATMENT OF CHRONİC DELTA HEPATİTİS-END OF TREATMENT RESULTS FROM THE LOWR HDV-2 STUDY

YURTAYDIN S. C., İDİLMAN R., KESKİN O., KALKAN Ç., KARAKAYA M. F., TUNÇ E., et al.
EASL Congress, Amsterdam, Hollanda, 19 - 23 Nisan 2017, cilt.66, ss.33, (Özet Bildiri)

132. VALUE OF NON-İNVASİVE FİBROSİS MARKERS İN CHRONİC HEPATİTİS D

KALKAN Ç., KARAKAYA M. F., KESKİN O., KARATAYLI E., BOZDAYI A. M., İDİLMAN R., et al.
52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Amsterdam, Hollanda, 19 - 23 Nisan 2017, cilt.66, ss.473, (Özet Bildiri)

133. New therapies for HCV

İDİLMAN R.
16th International Euroasian Congress of Gastroenterology and Surgery, 27 - 30 Nisan 2017, (Özet Bildiri)

134. EFFICIACY OF LEDİPASVİR AND SOFOSBUVİR WİTH/WİTHOUT TREATMENT OF CHRONIC HEPATITIS C PATIENTS WITH ADVANCED LIVER DISEASE RESULT OF A MULTICENTER TURKISH EARLY ACCES PROGRAM

İDİLMAN R., DEMİR M., ALADAĞ M., KAYMAKOĞLU S., EROL C., ÇAVUŞ B., et al.
VIRAL HEPATITIS (ENDORSED BY AASLD), 3 - 04 Mart 2017 Sürdürülebilir Kalkınma

135. Efficacy of ledipasvir and sofosbuvir with/without ribavirin for treatment of chronic hepatitis C patients with advanced liver disease results of a multicenter turkish early access program

İDİLMAN R., demir m., ALADAĞ M., KAYMAKOĞLU S., EROL C., cavus b., et al.
Viral Hepatitis, 3 - 04 Mart 2017, (Özet Bildiri) Sürdürülebilir Kalkınma

136. Efficacy of ledipasvir and sofosbuvir with/without ribavirin for treatmentof hepatitis C patients Results of a multicenter Turkish Early Access Program

İDİLMAN R., DEMİR M., ALADAĞ M., KAYMAKOĞLU S., CİHAN E., ÇAVUŞ B., et al.
Viral Hepatitis, 3 - 04 Mart 2017, (Özet Bildiri) Sürdürülebilir Kalkınma

137. The Role Of Genetic Variability Of PNPLA3 (rs738409) On Predispotion To Non-Alcoholic Fatty Liver Disease In Lean Patients

İDİLMAN R., Karatayli S. C., Karakaya F., Keskin O., Gozukara B., SAVAŞ B., et al.
67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, Amerika Birleşik Devletleri, 11 - 15 Kasım 2016, cilt.64, (Özet Bildiri)

138. The Prenylation Inhibitor Lonafarnib Can Induce Post-Treatment Alt Flares With Viral Clearance In Patients With Chronic Delta Hepatitis

Yurdaydin C., İDİLMAN R., Kalkan C., Karakaya F., Kartal A. C., Keskin O., et al.
67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, Amerika Birleşik Devletleri, 11 - 15 Kasım 2016, cilt.64, (Özet Bildiri)

139. Hepatocellular carcinoma (HCC) is the only factor affecting the excellent survival of Caucasian chronic hepatitis B (CHB) patients with or without cirrhosis under long-term entecavir (ETV) or tenofovir (TDF) therapy

Papatheodoridis G. V., Dalekos G. N., Yurdaydin C., van Boemmel F., Buti M., Sypsa V., et al.
67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, Amerika Birleşik Devletleri, 11 - 15 Kasım 2016, cilt.64, (Özet Bildiri)

140. Exploring Optimal Dosing Of Lonafarnib With Ritonavir For The Treatment Of Chronic Delta Hepatitis-Interim Results From The Lowr Hdv-2 Study

Yurdaydin C., İDİLMAN R., Kalkan C., Karakaya F., Kartal A. C., Keskin O., et al.
67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, Amerika Birleşik Devletleri, 11 - 15 Kasım 2016, cilt.64, (Özet Bildiri)

141. High incidence of significant liver fibrosis among HBeAg-positive patients with low levels of ALT

Sonneveld M. J., Brouwer W. P., Xie Q., Hansen B. E., TABAK Ö. F., İDİLMAN R., et al.
67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, Amerika Birleşik Devletleri, 11 - 15 Kasım 2016, cilt.64, (Özet Bildiri)

142. Chronic hepatitis D is a greater risk factor for hepatocellular carcinoma development than chronic hepatitis B

Keskin O., Karakaya F., KaIkon C., Kartal A. C., İDİLMAN R., Yurdaydin C.
67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, Amerika Birleşik Devletleri, 11 - 15 Kasım 2016, cilt.64, (Özet Bildiri)

143. The risk of hepatocellular carcinoma (HCC) is decreasing after the first 5 years of entecavir (ETV) or tenofovir (TDF) therapy in Caucasian chronic hepatitis B (CHB) patients

Papatheodoridis G. V., Yurdaydin C., Dalekos G. N., Buti M., Chi H., van Boemmel F., et al.
67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, Amerika Birleşik Devletleri, 11 - 15 Kasım 2016, cilt.64, (Özet Bildiri)

144. Hepatoselüler Kanserde Tedavi Yaklaşımı

İDİLMAN R.
Hepatoloji Okulu 2016, Türkiye, 13 - 15 Mayıs 2016 Sürdürülebilir Kalkınma

145. Hepatitis delta virus kinetics under the prenylation inhibitor lonafarnib suggest HDV metiadted suppression of HBV replication

YURTAYDIN S. C., Borochov N., KALKAN Ç., BedRoy S., KARATAYLI E., HaynesWilliams V., et al.
51th Annual Meeting of the European Association for the Study of the Liver (EASL), 13 - 17 Nisan 2016 Sürdürülebilir Kalkınma

146. Hepatitis B (HBV) Reactivation Rate and Fate Among Multiple Myeloma Patients Receiving Lenalidomide Containing Regimens: A Single Center Experience

Ataca P., Atilla E., Kircali E., İDİLMAN R., BEKSAÇ M.
57th Annual Meeting of the American-Society-of-Hematology, Florida, Amerika Birleşik Devletleri, 5 - 08 Aralık 2015, cilt.126, (Özet Bildiri) Sürdürülebilir Kalkınma

147. Decreasing risk of hepatocellular carcinoma (HCC) development after the first 5 years of entecavir (ETV) or tenofovir (TDF) therapy in Caucasian chronic hepatitis B (CHB) patients

Papatheodoridis G. V., İDİLMAN R., Dalekos G. N., Buti M., Chi H., van Boemmel F., et al.
66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), San-Francisco, Kostarika, 13 - 17 Kasım 2015, cilt.62, (Özet Bildiri) Sürdürülebilir Kalkınma

148. Prolongation of interferon therapy increases maintained virological response rates and improves the natural course of chronic delta hepatitis

Keskin O., Tuzun A., Karakaya F., Kalkan C., Kartal A. C., Karatayli E., et al.
66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), San-Francisco, Kostarika, 13 - 17 Kasım 2015, cilt.62, (Özet Bildiri) Sürdürülebilir Kalkınma

149. Hepatitis C Seropositivity is not as high as Western Countries in the Population Born Between 1945-1965 According to Turkey Nationwide Hepatitis Prevalence Study (TURKHEP 2010)

Ozdogan O. C., Tozun N., Kaymakoglu S., İDİLMAN R., KARASU A. Z., AKARCA U. S.
66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), San-Francisco, Kostarika, 13 - 17 Kasım 2015, cilt.62, (Özet Bildiri) Sürdürülebilir Kalkınma

150. "Normal" Serum ALT/AST Level in Turkish Population

KARASU A. Z., Tozun N., İDİLMAN R., Ozdogan O. C., Kaymakoglu S., Cakaloglu Y., et al.
66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), San-Francisco, Kostarika, 13 - 17 Kasım 2015, cilt.62, (Özet Bildiri)

151. Vena caval replacement with cadaveric caval graft for living donor liver transplantation in Budd Chiari syndrome associated with hydatid cyst surgery

BALCI D., KIRIMKER E. O., DURDU M. S., HAZİNEDAROĞLU S. M., MEÇO B. C., ÖZÇELİK M., et al.
ILTS 21st International Congress, 8 - 11 Temmuz 2015

152. ultiple Genetic Mutations Increasing Thrombotic Risk Predisposing Both Donor and Recipient Thrombotic Complications After Living Donor Liver Transplantation A Case Report

BALCI D., KIRIMKER E. O., konca c., HAZİNEDAROĞLU S. M., ÖZÇELİK M., MEÇO B. C., et al.
21th ILTS International Congress, 8 - 10 Temmuz 2015, (Tam Metin Bildiri)

153. Vena Caval Replacement With Cadaveric Caval Graft for Living Donor Liver Transplantation in Budd-Chiari Syndrome Associated With Hydatid Cyst Surgery: A Case Report

BALCI D., Kirimker O., Durdu S., HAZİNEDAROĞLU S. M., MEÇO B. C., ÖZÇELİK M., et al.
21st Annual International Congress of the International-Liver-Transplant-Society (ILTS), Illinois, Amerika Birleşik Devletleri, 8 - 11 Temmuz 2015, cilt.99, ss.247-248, (Özet Bildiri)

154. Multiple Genetic Mutations Increasing Thrombotic Risk Predisposing Both Donor and Recipient Thrombotic Complications After Living Donor Liver Transplantation: A Case Report

BALCI D., Kirimker O., KONCA C., HAZİNEDAROĞLU S. M., ÖZÇELİK M., MEÇO B. C., et al.
21st Annual International Congress of the International-Liver-Transplant-Society (ILTS), Illinois, Amerika Birleşik Devletleri, 8 - 11 Temmuz 2015, cilt.99, ss.278, (Özet Bildiri)

155. The role of genetic variability of pnpla3 (rs738409) on histological progression of non alcoholic fatty liver disease

İdilman R., Keskin O., Karataylı S., Kabaçam G., Tüzün A. E., Savaş B., et al.
24th Annual Conference of APASL, İstanbul, Türkiye, 12 - 15 Mart 2015, ss.373, (Özet Bildiri)

156. The role of genetic variability of pnpla3 rs738409 on histological progression of non alcoholic fatty liver disease

İDİLMAN R., KESKİN O., ÖZEN KARATAYLI S. C., KABAÇAM G., TÜZÜN A. E., SAVAŞ B., et al.
24th Annual Conference of APASL, March 12–15, 2015, Istanbul, Turkey, 12 - 15 Mart 2015, cilt.9, ss.373, (Özet Bildiri)

157. Prognostic factors for prediction of survival of hepatocellular cancer patients after selective internal radiation therapy

SOYDAL Ç., Keskin O., KÜÇÜK N. Ö., Bilgic S., ÖZKAN E., İDİLMAN R., et al.
Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI), Missouri, Amerika Birleşik Devletleri, 7 - 11 Haziran 2014, cilt.55, (Özet Bildiri) Sürdürülebilir Kalkınma

158. Hepatoselüler kanserli hastalarda selektif internal radyasyon tedavisi sonrası sağkalımı öngörmede prognostik faktörler

SOYDAL Ç., KESKİN O., KÜÇÜK N. Ö., İDİLMAN R., ÖZKAN E., BİLGİÇ M. S., et al.
26.Ulusal Nükleer Tıp Kongresi, Türkiye, 16 - 20 Nisan 2014, ss.17, (Özet Bildiri) Sürdürülebilir Kalkınma

159. Prenylation inhibition with lonafarnib decreases hepatitis D levels in humans

Koh C., Yurdaydin C., Cooper S., Cory D., Dahari H., Haynes-Williams V., et al.
65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Massachusetts, Amerika Birleşik Devletleri, 7 - 11 Kasım 2014, cilt.60, (Özet Bildiri) Sürdürülebilir Kalkınma

160. Early on-treatment HDV RNA kinetics are not predicitve for long-term response to a PEG-IFNa therapy of hepatitis delta

Wobse M., Yurdaydin C., Ernst S., Hardtke S., Heidrich B., Bremer B., et al.
65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Massachusetts, Amerika Birleşik Devletleri, 7 - 11 Kasım 2014, cilt.60, (Özet Bildiri) Sürdürülebilir Kalkınma

161. Timing of hepatocellular carcinoma (HCC) development and predictability of a modified PAGE-B risk score in caucasian chronic hepatitis B (CHB) patients treated with entecavir (ETV) or tenofovir (TDF)

Papatheodoridis G. V., Dalekos G. N., Sypsa V., Yurdaydin C., Buti M., Goulis I., et al.
65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Massachusetts, Amerika Birleşik Devletleri, 7 - 11 Kasım 2014, cilt.60, (Özet Bildiri) Sürdürülebilir Kalkınma

162. The long-term efficacy of combination of nucleos(t)ide analogue treatment and low dose hepatitis b immunoglobulin on posttransplant HBV recurrence

İDİLMAN R., Akyildiz M., Keskin O., Tuzun A., Yilmaz T. U., Guler N., et al.
65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Massachusetts, Amerika Birleşik Devletleri, 7 - 11 Kasım 2014, cilt.60, (Özet Bildiri) Sürdürülebilir Kalkınma

163. Risk and risk factors of hepatocellular carcinoma (HCC) in Caucasian chronic hepatitis B (CHB) patients with or without cirrhosis treated with entecavir (ETV) or tenofovir (TDF)

Papatheodoridis G. V., Dalekos G. N., Yurdaydin C., Goulis I., Arends P., Buti M., et al.
64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, Washington, Kiribati, 1 - 05 Kasım 2013, cilt.58, (Özet Bildiri) Sürdürülebilir Kalkınma

164. Inactive hepatitis B carriers are prone to HBsAg loss rather than reactivation: a 5-year prospective follow-up study

Keskin O., Yakut M., Kalkan C., Karatayli S. C., Karatayli E., İDİLMAN R., et al.
64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, Washington, Kiribati, 1 - 05 Kasım 2013, cilt.58, (Özet Bildiri) Sürdürülebilir Kalkınma

165. Four years of tenofovir monotherapy for NUC naive field practice European patients suppresses HBV replication in most patients with a favorable renal safety profile but does not prevent HCC in patients with or without cirrhosis

Lampertico P., Soffredini R., Yurdaydin C., İDİLMAN R., Papatheodoridis G. V., Margariti E., et al.
64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, Washington, Kiribati, 1 - 05 Kasım 2013, cilt.58, (Özet Bildiri)

166. Effectiveness and safety of entecavir and tenofovir in chronic hepatitis b patients: A multicenter Turkish study in clinical practice

İDİLMAN R., GÜNŞAR F., Keskin O., Meral C. E., KORUK M., GÜLŞEN M. T., et al.
64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, Washington, Kiribati, 1 - 05 Kasım 2013, cilt.58, (Özet Bildiri) Sürdürülebilir Kalkınma

167. INTERLEUKIN-28 (IL-28) GENE POLYMORPHISM (RS12979860 C/T) IS ASSOCIATED WITH PROGRESSION TO CHRONIC DELTA HEPATITIS INFECTION

BOZDAYI A. M., ÖZTÜRK T., Altuntas S., Karatayli S. C., Karatayli E., Celik I., et al.
62nd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), San-Francisco, Kostarika, 4 - 08 Kasım 2011, cilt.54, (Özet Bildiri) Sürdürülebilir Kalkınma

168. IDENTIFICATION OF RISK FACTORS FOR FIBROSIS PROGRESSION IN NON-ALCOHOLIC FATTY LIVER DISEASE

CENGİZ SEVAL G., İDİLMAN R., ÇINAR K., Seven G., Yakut M., Kabacam G., et al.
61st Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Massachusetts, Amerika Birleşik Devletleri, 29 Ekim - 02 Kasım 2010, cilt.52, (Özet Bildiri)

169. HBsAg POZİTİF OLAN ALICILARDA ALLOJENİK HEMATOPOETİK HÜCRE TRANSPLANTASYONU

TOPÇUOĞLU P., SOYDAN E., İDİLMAN R., CENGİZ SEVAL G., ÜSTÜN C., ARSLAN Ö., et al.
35. Ulusal Hematoloji Kongresi, 07 Ekim 2009, (Tam Metin Bildiri)

170. RENAL TUBULER ACIDOSIS IN LIVER TRANSPLANT RECIPIENTS: THE EFFECT OF CALCINEURIN INHIBITORS.

İDİLMAN R., KARASU A. Z., Cengiz G., KEVEN K., Ersoz S., ŞENGÜL Ş., et al.
15th Annual Congress of the International-Liver-Transplantation-Society, New York, Amerika Birleşik Devletleri, 8 - 11 Temmuz 2009, cilt.15, (Özet Bildiri)

171. The burden of chronic hepatitis B in a median endemic country:a mathematical approach

TOY M., ÖNDER F. O., İDİLMAN R., Richardus J. H., BOZDAYI A. M., KULOĞLU Z., et al.
International Liver Congress TM 2009. 44th Annual Meeting of The European Association for the Study of the Liver,Copenhagen, Denmark, 22-26 April, 200, Copenhag, Danimarka, 22 - 26 Nisan 2009, (Özet Bildiri)

172. Kronik Hepatit C’li hastalarda karaciğer fibrozisini göstermede kullanılan biyokimyasal belirteçler ile karaciğer biyopsisinin tanısal değerliliklerinin karşılaştırılması

MIZRAK KAYA D., İDİLMAN R., DOĞANAY ERDOĞAN B., SAVAŞ B., üstün y., Saykı M., et al.
25. Ulusal Gastroenteroloji Haftası, Türkiye, 12 - 16 Kasım 2008, (Tam Metin Bildiri)

173. Non-Alkolik Yağlı Karaciğer: Uzun Süreli İlaçsız Takipte Doğal Seyir

CENGİZ SEVAL G., İDİLMAN R., ÇINAR K., MIZRAK KAYA D., BOZKUŞ Y., Saykı M., et al.
25. Ulusal Gastroenteroloji Haftası, Türkiye, 12 - 16 Kasım 2008, (Tam Metin Bildiri)

174. Non-alkolik yağlı karaciğerde endotelyal fonksiyon ve kardiovasküler risk profili

Saykı M., İDİLMAN R., TULUNAY KAYA C., MIZRAK KAYA D., Bıyıklı Z., CENGİZ SEVAL G., et al.
25. Ulusal Gastroenteroloji Haftası, Türkiye, 12 - 16 Kasım 2008, (Tam Metin Bildiri)

175. Kronik Viral Hepatitlerde Lenfoproliferatif Hastalıklar

BOZKUŞ Y., İDİLMAN R., MIZRAK KAYA D., CENGİZ SEVAL G., Saykı M., Üstün Y., et al.
25. Ulusal Gastroenteroloji Haftası, Türkiye, 12 - 16 Kasım 2008, (Tam Metin Bildiri)

176. HBEAG-POSITIVE DELTA HEPATITIS: VIROLOGICAL; BIOCHEMICAL AND CLINICAL FEATURES IN A LARGE EUROPEAN MULTICENTER DATA BASE

Heidrich B., Wedemeyer H., Bektas M., İDİLMAN R., Oender F. O., BOZDAYI A. M., et al.
59th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, San-Francisco, Kostarika, 31 Ekim - 04 Kasım 2008, cilt.48, (Özet Bildiri) Sürdürülebilir Kalkınma

177. Complete genome sequences and phylogenetic analysis of hepatitis D viruses (HDV) isolated from turkish patients with chronic HDV infection

Emir F., Bektas M., Kesen E., Idilman R., Bozdayi A. M., Yurdaydin C.
58th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Massachusetts, Amerika Birleşik Devletleri, 2 - 06 Kasım 2007, cilt.46, (Özet Bildiri)

178. Transjuguler Intrahepatik Portosistemik Santin Renal Resistivite indeksi Üzerine Etkileri: Erken Sonuclar

CENGİZ SEVAL G., İDİLMAN R., ÇINAR K., KEVEN K., ÇOBAN Ş., BEKTAŞ M., et al.
23. Ulusal Gastroenteroloji Kongresi, 05 Kasım 2006, (Tam Metin Bildiri)

179. Potential role of cytokine gene polymorphisms in outcome of chronic delta hepatitis

Ulger Z., Emir F., Arslan-Ergul A., Idilman R., Yalcin K., Uzunalimoglu O., et al.
57th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Massachusetts, Amerika Birleşik Devletleri, 27 - 31 Ekim 2006, cilt.44, (Özet Bildiri)

180. Insulin-sensitizer agents in the treatment of individuals with non-alcoholic steatohepatitis: A preliminary report

Idilman R., Mizrak D., Soykan I., Corapcioglu D., Erden E., Coban S., et al.
57th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Massachusetts, Amerika Birleşik Devletleri, 27 - 31 Ekim 2006, cilt.44, (Özet Bildiri)

181. Treatment of chronic hepatitis D (CHD) with interferon vs. interferon plus lamivudine vs. lamivudine: Short-and long-term results

Yurdaydin C., Bozkaya H., Onder O., Senturk H., Fried M., Idilman R., et al.
56th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, San-Francisco, Kostarika, 11 - 15 Kasım 2005, cilt.42, (Özet Bildiri) Sürdürülebilir Kalkınma

182. The fate of recipient-derived repopulated hepatocytes in sex-mismatched liver allograft: A longitudinal study

Idilman R., Erden E., Ersoz S., Kuzu I., Karayalcin S.
56th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, San-Francisco, Kostarika, 11 - 15 Kasım 2005, (Özet Bildiri)

183. The effect of tissue injury on donor-derived hepatocyte repopulation following sex-mismatched hematopoietic stem cell transplantation

Idilman R., Soykan I., Erden E., Kuzu I., Arat M., Akyol G., et al.
40th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Paris, Fransa, 13 - 17 Nisan 2005, cilt.42, ss.139, (Özet Bildiri)

184. Potential role of cytokine gene polymorphisms in hepatitis B infection outcome

Arslan-Ergul A., Yurdaydin C., Koytak E., Idilman R., Uzunalimoglu O., Bozdayi A., et al.
40th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Paris, Fransa, 13 - 17 Nisan 2005, cilt.42, ss.230, (Özet Bildiri) Sürdürülebilir Kalkınma

185. The expression of intestinal trefoil factor in biliary epithelial cells of chronic graft-versus-host disease of the liver in allogeneic hematopoietic stem cell transplants

Idilman R., Erden E., Arat M., Coban S., Erkan O., Tuzun A., et al.
40th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Paris, Fransa, 13 - 17 Nisan 2005, ss.236, (Özet Bildiri)

186. The effects of transplantation-related factors and tissue injury on donor-derived cells repopulation following sex-mismatched haematopoietic cell transplantation

Idilman R., Kuzu L., Arat M., Erden E., Soydan E., Soykan I., et al.
31st Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/21st Meeting of the EBMT-Nurses-Group/4th Meeting of the EBMT-Data-Management-Group, Prague, Çek Cumhuriyeti, 20 - 23 Mart 2005, cilt.35, (Özet Bildiri)

187. PPAR-alpha L162V polymorphism in nonalcoholic steatohepatitis.

Verdi H., Koytak E., Ergul A., Idilman R., Uzunalimoglu O., Yurdaydin C., et al.
55th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, Amerika Birleşik Devletleri, 29 Ekim - 02 Kasım 2004, cilt.40, (Özet Bildiri)

188. Hepatit C Virus Enfeksiyonu Olan hastalarda Cinsel İşlev Bozuklukları

BOZTAŞ M. H., İDİLMAN R., ÖZEL KIZIL E. T., TÜZÜN A. E., SOYKAN A., BOZKAYA H., et al.
21. Ulusal Gastroenteroloji Kongresi, Türkiye, 31 Ağustos - 04 Eylül 2004, (Tam Metin Bildiri)

189. Recipient-derived hepatocytes in sex-mismatched liver allograft after liver transplantation

Idilman R., Erden E., Kuzu I., Ersoz S., Karayalcin K., KARASU A. Z., et al.
39th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Berlin, Almanya, 14 - 18 Nisan 2004, ss.104, (Özet Bildiri)

190. Recipient-derived hepatocytes in sex-mismatched living-related partial liver transplants.

Idilman R., Erden E., Kuzu I., Ersoz S., Karayalcin K., Yerdel M., et al.
54th Annual Meeting of the American-Association-for-the-Study-of-Liver-Disease, BOSTON, MASSACHUSETTS, 24 - 28 Ekim 2003, (Özet Bildiri)

191. Lamivudine prophylaxis for prevention of chemotherapy induced hepatitis B virus reactivation in hepatitis B virus carriers with hematological malignancies

Idilman R., Arat M., TÖRÜNER M., Soykan I., Karayalcin S., Soydan E., et al.
38th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, İstanbul, Türkiye, 29 Mart - 01 Nisan 2003, cilt.38, ss.146-147, (Özet Bildiri) Sürdürülebilir Kalkınma

192. The effect of hepatitis B virus status of the donor on the hepatitis B virus serology of the recipient after allogeneic hematopoietic cell transplantation

Idilman R., Soydan E., Arat M., TÖRÜNER M., Soykan I., Karayalcin S., et al.
38th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, İstanbul, Türkiye, 29 Mart - 01 Nisan 2003, cilt.38, ss.146, (Özet Bildiri)

193. The effect of mycophenolate mofetil in steroid refractory or dependent chronic graft-versus-host disease

Soydan E., Arat M., Topcuoglu P., Ozcan M., Arslan O., Idilman R., et al.
29th Annual Meeting of the European Group for Blood and Marrow Transplantation/19th Meeting of the EBMT Nurses Group/2nd Meeting of the EBMT Data Management Group, İstanbul, Türkiye, 23 - 26 Mart 2003, cilt.31, (Özet Bildiri)

194. The effect of hepatitis B virus status of donor on the hepatitis B virus serology of recipient after allogeneic hematopoietic cell transplantation

Soydan E., Idilman R., Arat M., Karayalcin S., Ustun C., Ozcan M., et al.
29th Annual Meeting of the European Group for Blood and Marrow Transplantation/19th Meeting of the EBMT Nurses Group/2nd Meeting of the EBMT Data Management Group, İstanbul, Türkiye, 23 - 26 Mart 2003, cilt.31, (Özet Bildiri)

195. Donor type epithelial cell repopulation in gastrointestinal mucosa following sex mismatch allogeneic peripheral blood transplantation: evidence for in vivo stem cell plasticity?

Kuzu I., Idilman R., Arat M., Dalva K., Soykan I., Akan H., et al.
29th Annual Meeting of the European Group for Blood and Marrow Transplantation/19th Meeting of the EBMT Nurses Group/2nd Meeting of the EBMT Data Management Group, İstanbul, Türkiye, 23 - 26 Mart 2003, (Özet Bildiri)

196. The efficciency of ursodeoxycholic acid in treatment of limited chronic graft versus host disease of the liver.

Arat M., Idilman R., Soydan E., TÖRÜNER M., Akan H.
44th Annual Meeting of the American-Society-of-Hematology, PHILADELPHIA, PENNSYLVANIA, 6 - 10 Aralık 2002, cilt.100, (Özet Bildiri)

197. The long-term ursodeoxycholic acid treatment of chronic graft-versus-host disease of the liver.

Idilman R., Arat M., TÖRÜNER M., Soydan E., Soykan I., Erden E., et al.
53rd Annual Meeting of the Association-for-the-Study-of-Liver-Diseases (AASLD), BOSTON, MASSACHUSETTS, 1 - 05 Kasım 2002, cilt.36, (Özet Bildiri)
Kitaplar 1

1. Türkiye Viral Hepatit Önleme ve Kontrol Programı” “Sağlık Bakanlığı Yayın No, Ankara

AKARCA U. S., AKINCI E., AKYILDIZ M., BAYKAM N., BEŞIŞIK S. F., BODUR H., et al.
Sağlık Bakanlığı yayını Ankara, Ankara, 2018 Sürdürülebilir Kalkınma
Metrikler

Yayın

475

Yayın (WoS)

345

Yayın (Scopus)

267

Atıf (WoS)

7910

H-İndeks (WoS)

42

Atıf (Scopus)

11190

H-İndeks (Scopus)

47

Atıf (Scholar)

15425

H-İndeks (Scholar)

56

Atıf (TrDizin)

33

H-İndeks (TrDizin)

3

Atıf (Diğer Toplam)

33

Proje

13

Tez Danışmanlığı

13

Açık Erişim

51
BM Sürdürülebilir Kalkınma Amaçları
SDG 3: AMAÇ 3: SAĞLIKLI BİREYLER
SDG 4: AMAÇ 4: NİTELİKLİ EĞİTİM
SDG 16: AMAÇ 16: BARIŞ VE ADALET
SDG 17: AMAÇ 17: AMAÇLAR İÇİN ORTAKLIKLAR